11 April 2012

McKesson has been selected by the Department of Veterans Affairs (VA), which runs the nation's largest integrated healthcare system, to continue as the VA's prime pharmaceutical supplier.

The two-year agreement calls for McKesson to supply all of the VA's medical centers and outpatient clinics, as well as the VA's Consolidated Mail Outpatient Pharmacies (CMOPs).

Nestlé has prevailed in the steeplechase for Pfizer's ($PFE) nutrition unit.

The price was $11.85 billion, rather than the $10 billion estimated by analysts.

All the more cash for Pfizer to share with investors and invest in its core pharma business.

The nutrition-unit sale comes as Pfizer is readying a spinoff of its animal health business.

The drugmaker announced its plans to shed both units last summer as part of a restructuring designed to streamline the company and focus attention on its branded-drug nucleus.

Abbott has reached a settlement with U.S. federal and 49 state authorities, plus the District of Columbia, to resolve all outstanding issues regarding a previously disclosed investigation of past sales and marketing practices relating to its neurologic medication Depakote.

The settlement results from a four-year-old investigation into past sales activities that began in 1998 involving this product.

Abbott cooperated fully with the government during its investigation.

Abbott will pay $800 million to resolve civil allegations split among federal and state governments, $700 million for a criminal penalty, and $100 million to states to resolve consumer protection matters.

These amounts were previously reserved in anticipation of today's agreement.

As part of the resolution, Abbott has agreed to plead guilty to one misdemeanor violation of the Food, Drug and Cosmetic Act for misbranding.

The company also agreed to certain other conditions of settlement, including the maintenance of specified compliance measures and annual certification regarding its state of compliance by its CEO and Board of Directors during a five-year probationary period.

Abbott will also enter into a Corporate Integrity Agreement (CIA) with the Office of Inspector General of the U.S. Department of Health and Human Services.

The CIA will govern Abbott's compliance program for a period of five years and builds upon the company's existing comprehensive compliance program.

The CIA will also transfer to AbbVie upon separation.

The settlement is subject to approval by the Federal Court in the Western District of Virginia.

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics.

The company employs approximately 91,000 people and markets its products in more than 130 countries.

Abbott and Galapagos have entered into a global collaboration to develop and commercialize an oral, next-generation JAK1 inhibitor in Phase II development with the potential to treat multiple autoimmune diseases.

GLPG0634 is a highly selective JAK1 inhibitor that Galapagos is developing for the treatment of rheumatoid arthritis (RA) and other autoimmune diseases.

The Janus kinases (JAK) are a family of enzymes that play a key role in the signaling mechanism used by a number of cytokines that are involved in autoimmune diseases.

Abbott will make an initial upfront payment of $150 million for rights related to the global collaboration.

Upon successful completion of the RA Phase II studies, Abbott will license the program for a one-time fee of $200 million if the studies meet certain pre-agreed criteria.

Abbott will assume sole responsibility for Phase III clinical development and global manufacturing.

Pending achievement of certain developmental, regulatory, commercial and sales-based milestones, Galapagos would be eligible to receive additional milestone payments from Abbott, potentially amounting to $1.0 billion, in addition to tiered double-digit royalties on net sales upon commercialization.

Galapagos retains co-promotion rights in Belgium, the Netherlands and Luxembourg.

Merck have entered into an agreement to develop and commercialize Endocyte's novel investigational therapeutic candidate vintafolide (EC145).

Vintafolide is currently being evaluated in a Phase III clinical trial for platinum-resistant ovarian cancer, (PROCEED trial) and a Phase II trial for non-small cell lung cancer (NSCLC); both studies are also using Endocyte's investigational companion diagnostic agent, etarfolatide (EC20).

Under the agreement, Merck, through a subsidiary, will gain worldwide rights to develop and commercialize vintafolide.

Endocyte will receive a $120 million upfront payment and is eligible for milestone payments of up to $880 million based on the successful achievement of development, regulatory and commercialization goals for vintafolide for a total of six cancer indications.

In addition, if vintafolide receives regulatory approval, Endocyte will receive an equal share of the profit in the United States (U.S.) as well as a double digit percentage royalty on sales of the product in the rest of the world.

Endocyte has retained the right to co-promote vintafolide with Merck in the U.S. and Merck has the exclusive right to promote vintafolide in the rest of world.

Endocyte will be responsible for the majority of funding and completion of the PROCEED trial.

Merck will be responsible for all other development activities and costs and have all decision rights for vintafolide.

Endocyte remains responsible for the development, manufacture and commercialization worldwide of etarfolatide, a non-invasive companion diagnostic imaging agent that is used to identify folate receptor positive tumor cells.

FORMA Therapeutics has entered into a research and development collaboration with Boehringer Ingelheim to discover and develop novel drug candidates for the treatment of cancer.

The agreement will focus on discovering small molecule drugs against oncology-relevant protein-protein interactions.

FORMA will receive a total of $65 million in up-front payments and research funding to screen for and optimize compounds against multiple oncology targets over the next four years.

FORMA could be eligible for up to $750 million in pre-commercial milestones for programs resulting from the collaboration.

Further financial details were not disclosed.

13 pharmaceutical companies, the U.S., U.K. and U.A.E governments, the Bill & Melinda Gates Foundation, the World Bank and other global health organisations announced a new, coordinated push to accelerate progress toward eliminating or controlling 10 neglected tropical diseases (NTDs) by the end of the decade.

Uniting efforts with NTD-endemic countries, partners pledged to bring a unique focus to defeating these diseases and to work together to improve the lives of the 1.4 billion people worldwide affected by NTDs, most of whom are among the world's poorest.

In the largest coordinated effort to date to combat NTDs, the group announced at an event at the Royal College of Physicians that they would: sustain or expand existing drug donation programs to meet demand through 2020; share expertise and compounds to accelerate research and development of new drugs; and provide more than US$785 million to support R&D efforts and strengthen drug distribution and implementation programmes.

To guide the effort against NTDs, the World Health Organisation (WHO) this week unveiled a new strategy, Accelerating work to overcome the global impact of neglected tropical diseases-A roadmap for implementation, that sets targets for what can be achieved by the end of the decade.

New commitments from partners will close the funding gap to eradicate Guinea worm disease and expedite progress toward the 2020 goals of elimination for lymphatic filariasis, blinding trachoma, sleeping sickness and leprosy, and control of soil-transmitted helminthes, schistosomiasis, river blindness, Chagas disease and visceral leishmaniasis.

With new and existing pledges totaled, companies will donate an average of 1.4 billion treatments each year to those in need, according to the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA).

In addition, new research and development collaborative efforts and access agreements with 11 companies and the R&D organisation Drugs for Neglected Diseases initiative (DNDi) are providing unprecedented access to compound libraries that could lead to new treatments.

These commitments will work in parallel with other efforts to speed the development of critical NTD treatments, including WIPO Re:Search, a database of research compounds, knowledge and expertise.

The U.S. Agency for International Development (USAID) also announced an $89 million appropriation by the U.S. Congress to strengthen drug delivery and distribution programmes, building on its US$212 million investment since 2006.

In addition, the World Bank will extend its financing and technical support to help African countries build stronger community health systems that will integrate NTD elimination and control, as well as work with other partners to expand a trust fund to combat river blindness to other preventable NTDs in Africa.

The governments of Bangladesh, Brazil, Mozambique and Tanzania, where NTDs are endemic, announced that they would implement integrated plans to defeat NTDs and devote political and financial resources to combat these diseases.

All partners pledged accountability by exploring mechanisms to regularly track progress toward the 2020 goals.

SPECIFIC PARTNER COMMITMENTS ANNOUNCED TODAY INCLUDE:

Sustaining, Expanding and Extending Drug Supply:

All companies with NTD drug donation programs pledged to sustain or extend their programs to the end of the decade, and some pledged to increase their commitments.

Royalty Pharma acquired an interest in the earn-out payable to the former shareholders of Fumapharm AG for $761 million in cash.

The Fumapharm earn-out primarily represents an indirect interest in Biogen Idec's BG-12 (dimethyl fumarate), an oral therapeutic candidate for the treatment of relapsing-remitting multiple sclerosis (RRMS).

The earn-out also includes an interest in Fumaderm, a therapeutic approved in Germany for the treatment of moderate to severe plaque psoriasis.

RUSNANO and Domain Associates announced a partnership that will spur modernization of the Russian healthcare market by bringing next-generation pharmaceuticals, medical devices and diagnostics to Russia.

RUSNANO and Domain have signed an investment agreement under which they will jointly invest in emerging life sciences technology companies, foster transfer of technology into Russia, and establish manufacturing facilities in Russia for production of advanced therapeutic products for the treatment of medical conditions including viral infections, cardiovascular diseases, cancer, and others.

RUSNANO and Domain's venture capital funds will co-invest in approximately 20 US-based healthcare technology companies.

Target companies will include groups developing innovative products in the fields of pharmaceuticals, biotechnology, medical devices and other areas of life sciences, that have significant applications for patient populations in Russia, and that complement RUSNANO's focus on nanotechnology-based innovation.

RUSNANO and Domain will jointly establish a pharmaceutical and medical device manufacturing facility in Russia that meets GMP standards.

The joint venture will leverage the innovations created by Domain and RUSNANO's investment portfolio companies, and will obtain exclusive rights to manufacture and market products based on these innovations in Russia and the CIS.

RUSNANO and Domain's venture capital funds, together with other co-investors, are expected to invest approximately $760 million into portfolio companies and the manufacturing facility in Russia.

The joint venture will manage advanced-stage clinical trials in Russia of new pharmaceuticals and other products that will support regulatory approval of these products in Russia, the United States and other markets.

BD (Becton, Dickinson and Company) has signed a definitive agreement to sell its BD Biosciences - Discovery Labware unit, excluding its Advanced Bioprocessing platform, to Corning.

The transaction will be a cash sale for approximately $730 million, subject to post-closing adjustment for inventory balances.

FORMA Therapeutics announced an exclusive alliance with Janssen Biotech in which the two companies will collaborate on the discovery, development and commercialization of novel small molecule drug candidates that target tumor metabolism mechanisms.

Under the terms of the research collaboration and license option agreement, FORMA will discover and develop drugs against a panel of tumor metabolism targets.

FORMA may receive project and milestone funding over several years of up to $700 million if development, regulatory and commercialization milestones are achieved for drug candidates successfully launched through the collaboration.

FORMA may be eligible for royalties on revenues from commercialized products as a result of this collaboration.

Further, if certain milestones are achieved during the initial phase of the collaboration, FORMA will have the opportunity to co-develop and maintain North American commercial rights to one program of Janssen’s selection.

In addition, the parties can expand the collaboration to include additional targets, including areas beyond tumor metabolism.

Xenon in a strategic alliance with Genentech to discover and develop compounds and companion diagnostics for the potential treatment of pain.

Xenon and Genentech will collaborate on the discovery of new therapeutic approaches for treating pain.

Genentech has an exclusive license to compounds and a non-exclusive license to diagnostics from Xenon for development and commercialization of products.

Xenon will receive an undisclosed upfront payment, research funding and is eligible to receive research, development and commercialization milestone payments, totaling up to $646 million for multiple products and indications.

In addition, Xenon will receive royalties on sales of products resulting from the collaboration.

Omega Pharma has reached agreement to acquire the previously identified non-core OTC brands of GlaxoSmithKline (GSK) in Europe for EUR 470 million in cash.

This transaction builds on the recently announced divestment by GSK of certain non-core OTC brands in the USA and Canada, the majority ofwhich was completed at the end of January 2012.

The brands being acquired include Lactacyd, Abtei, Solpadeine, Zantac, Nytol and Beconase and generated sales of over EUR 200 million in 2011.

The transaction is expected to be completed in the second quarter of 2012, subject to regulatory approvals.

As part of the agreement, Omega has also agreed to purchase the Herrenberg manufacturing site which is located in Germany and employs approximately 110 people.

A number of the brands that are being acquired are manufactured at Herrenberg and it is anticipated that existing employees will transferwith the site to Omega Pharma under the provisions of German employment law.

The proposed transaction will also provide Omega Pharma with the required critical mass in a number of key European markets – i.e. Germany, the UK, Poland and Italy.

11 April 2012

Threshold Pharmaceuticals has earned a $20 million milestone payment from Merck KGaA for achieving a statistically significant progression free survival benefit in its 214-patient randomized controlled Phase 2 clinical trial ("404 trial") evaluating the efficacy and safety of two doses of TH-302, a hypoxia-targeted drug, in combination with gemcitabine compared to gemcitabine alone in patients with first-line advanced pancreatic cancer.

3 February 2012

Threshold Pharmaceuticals announced that a global agreement was signed with Merck KGaA to co-develop and commercialize TH-302, Threshold's small molecule hypoxia-targeted drug.

TH-302 is currently being investigated in a global Phase 3 clinical trial in patients with soft tissue sarcoma, a randomized Phase 2 trial in patients with advanced pancreatic cancer from which top-line results are expected in February, as well as additional clinical studies in other solid tumors and hematological malignancies.

Under the terms of the agreement, Merck will receive co-development rights, exclusive global commercialization rights and will provide Threshold an option to co-commercialize the therapeutic in the United States.

In exchange, Threshold will receive an upfront payment of $25 million and could receive up to $35 million in additional development milestones during 2012.

Threshold is also eligible to receive a $20 million milestone payment based on positive results from its randomized Phase 2 trial in pancreatic cancer.

Total potential milestone payments are $525 million, comprised of $280 million in regulatory and development milestones and $245 million in sales-based milestones.

In the United States, Threshold will have primary responsibility for development of TH-302 in the soft tissue sarcoma indication.

Threshold and Merck KGaA will jointly develop TH-302 in all other cancer indications being pursued.

Merck KGaA will pay 70% of worldwide development costs for TH-302.

Subject to FDA approval in the United States, Merck KGaA will initially be responsible for commercialization of TH-302 with Threshold receiving a tiered, double-digit royalty on sales.

Under the royalty-bearing portion of the agreement, Threshold retains the option to co-promote TH-302 in the United States.

Additionally, Threshold retains the option to co-commercialize TH-302 allowing the company to participate in up to 50% of the profits in the United States based on certain revenue tiers.

Outside of the United States, Merck KGaA will be solely responsible for the commercialization of TH-302 with Threshold receiving a tiered, double-digit royalty on sales in these territories.

Morrison & Foerster LLP acted as legal counsel for Threshold in this transaction.

Pall Corporation announced it has entered into an agreement to sell certain assets of its blood collection, filtration and processing product lines to Haemonetics Corporation for approximately $550 million.

Assets included in the transaction are Pall’s portfolio of blood collection, processing and filtration systems and equipment for transfusion medicine.

The transaction will involve the transfer of manufacturing facilities in Covina, California; Tijuana, Mexico; Ascoli, Italy and a portion of Pall’s operations in Fajardo, Puerto Rico.

Separate from these manufacturing facilities, Pall will also transfer related blood media manufacturing capability to Haemonetics.

The transfer of the related media lines is expected to be completed by 2016.

Until that time, Pall will provide these media products under a supply agreement.

Upon closing, approximately 1,300 employees will transition to Haemonetics.

Under the terms of the agreement, approximately $535 million will be paid upon closing.

The Company estimates that the after-tax proceeds related to this payment will be approximately $430 million.

The balance will be payable upon Pall’s delivery of certain media assets to Haemonetics.

The Company expects to record an after-tax gain of $230 million to $240 million, or $1.95 to $2.04 per share, upon closing.

Final determination of cash proceeds, gain on sale and tax impact are subject to working capital and certain other adjustments and final allocation of proceeds by jurisdiction. The transaction, which is expected to close at the beginning of Pall’s fiscal year 2013, is subject to certain closing conditions, regulatory approvals and labor-related notifications.

Headquartered in Braintree, Massachusetts, Haemonetics is a global healthcare company dedicated to providing innovative blood management solutions.

Brian Concannon, Haemonetics' President and CEO, commented, "We believe this is an important and exciting step toward serving the manual whole blood collection market. The assets from Pall will provide us with a meaningful commercial presence in all aspects of whole blood collection, with leading filter technology and manufacturing capability, a broad portfolio of manual collection and processing products, and stronger relationships with major blood authorities and key customers we have in common. This transaction will enable Haemonetics to present the broadest product offering to our customers to address their needs in the whole blood market."

Larry Kingsley, President and CEO of Pall said, "We believe Haemonetics will be a strong, strategically advantaged owner of these assets. We are proud of our employees whose contributions to the blood market will now be strengthened by their alignment with Haemonetics. We also believe our existing customers will immediately benefit from Haemonetics’ extended portfolio of blood management solutions. As a result of the transaction, Pall will increase its focus on businesses and markets where our competitive advantages are greatest. The impact of this decision is that Pall's overall profitability profile and long-term growth rate will be enhanced."

Revenue for the product lines being divested is expected to be approximately $230 million in Pall’s fiscal year 2012, inclusive of OEM sales to Haemonetics. Operating profit for fiscal 2012 is expected to be about $60 million. The Company estimates that the blood product line will contribute approximately $0.38 to EPS in fiscal year 2012, net of pro forma tax effect. Cost reductions and profit from the supply agreement are expected to largely offset any long-term dilution from the transaction.

The company is currently evaluating various options for the anticipated cash proceeds, including long-term growth strategies and short-term shareholder returns.

Pall expects to report the results of the blood product line, net of pro forma tax effect, as a discontinued operation for all periods presented beginning with its third quarter earnings release and Form 10-Q. The after-tax gain will also be reflected in discontinued operations in the period the transaction closes.

Webcast Information

The company will host a webcast at 10:00 a.m. EDT on Monday, April 30, 2012 to discuss the transaction. The webcast will be available at www.pall.com/irevents events or at http://www.media-server.com/m/p/34wfiy8k

About Pall Corporation

Pall Corporation (NYSE: PLL) is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The Company’s engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation, with total revenues of $2.7 billion for fiscal year 2011, is an S&P 500 company with almost 11,000 employees serving customers worldwide. Pall has been named a “top green company” by Newsweek magazine. To see how Pall is helping enable a greener, safer, more sustainable future, follow us on Twitter @PallCorporation or visit www.pall.com/irevents.

11 January 2011

Eli Lilly and Boehringer Ingelheim have a global agreement to jointly develop and commercialize a portfolio of diabetes compounds currently in mid- and late-stage development.

Included are Boehringer Ingelheim's two oral diabetes agents-linagliptin and BI10773-as well as Lilly's two basal insulin analogues-LY2605541 and LY2963016-as well as the option to co-develop and co-commercialize Lilly's anti-TGF-beta monoclonal antibody.

The agreement also includes an option for Boehringer Ingelheim to co-develop and co-commercialize another Lilly diabetes molecule, an anti-TGF-beta monoclonal antibody, which is currently in Phase II of clinical testing in patients with diabetes with chronic kidney disease.

Lilly will make an initial one-time payment to Boehringer Ingelheim of euro 300 million.

Boehringer Ingelheim will be eligible to receive up to a total of euro 625 million in success-based regulatory milestones for linagliptin and BI10773.

Lilly will be eligible to receive up to a total of $650 million in success-based regulatory milestones on its two basal analogue insulins.

Should Boehringer Ingelheim elect to opt-in to the Phase III development and potential commercialization of the anti-TGF-beta monoclonal antibody, Lilly would be eligible for up to $525 million in opt-in and success-based regulatory milestone payments.

The companies will share ongoing development costs equally.

Upon successful regulatory approval of any product resulting from the alliance, the companies will equally share in the product's commercialization costs and gross margin.

Each company will also be entitled to potential performance payments on sales of the molecules they contribute to the collaboration.

Long-term agreement for the development and commercialization of up to five innovative psychiatric and neuroscience products worldwide.

The agreement covers up to five early and late stage compounds in development.

The two late stage compounds are from Otsuka: aripiprazole depot formulation and OPC-34712.

Otsuka receives the rights to enter into co-development, and eventual co-promotion following approval, of up to three compounds after Phase IIb clinical trials.

The alliance is a sales and cost share agreement.

Lundbeck will make an upfront payment upon signing of USD 200 million.

Otsuka will in total receive up to approximately USD 1.4 billion from Lundbeck as upfront payment and development and regulatory milestone payments.

With the addition of sales milestones in connection, Lundbeck will pay up to approximately USD 1.8 billion to Otsuka.

Both companies will share the sales and development and commercialization costs based on the agreement.

For aripiprazole depot formulation, Lundbeck will receive 50% of net sales in Europe (EU5 and the 4 Nordic countries) and Canada and 20% of net sales in the U.S. from Otsuka.

The cost incurred for the development and promotion will be shared in the same ratio.

Otsuka holds the rights in many of the Asian countries including Japan, as well as Turkey and Egypt.

For the remaining markets in the Lundbeck territories, Lundbeck will market the compound and Otsuka will supply the bulk product at a price of agreed percentage of the sales.

For OPC-34712, Lundbeck will receive 50% of net sales in Europe (EU5 and the 4 Nordic countries) and Canada and 45% of net sales in the U.S. from Otsuka.

The cost incurred for the promotion will be shared in the same ratio.

Otsuka holds the rights in many of the Asian countries including Japan, as well as Turkey and Egypt.

For the remaining markets in the Lundbeck territories, Lundbeck will market the compound, and Otsuka will supply the bulk product at a price of agreed percentage of the sales.

For the development costs of OPC-34712, Otsuka will be responsible up to certain amount and equally share the costs afterwards.

In co-commercialization countries, the parties will share sales efforts and costs in accordance with the territory split.

In the U.S., Canada, EU5 and the 4 Nordic countries, Otsuka will book all sales.

In the rest of Europe and the world, excluding many of the Asian countries, as well as Turkey and Egypt, Lundbeck will book all sales and take full responsibility for commercialization.

Otsuka will retain the rights to participate in the co-development and co-marketing when it establishes a sales organization in Lundbeck's territory.

Terminated their alliance for exenatide and resolve the outstanding litigation between the companies.

As part of the agreement, the parties will transition full responsibility for the worldwide development and commercialization of exenatide to Amylin, starting in the United States (U.S.) on November 30, 2011, and progressing to all markets by the end of 2013.

After nearly a decade-long partnership that achieved a number of important milestones on behalf of people living with diabetes, the companies determined it was in the best interest of all constituents to amicably terminate the collaboration.

Both companies are committed to ensuring a seamless transition of global product responsibility to Amylin while maintaining continuity of patient care.

Amylin will make a one-time, upfront payment to Lilly of $250 million.

Amylin will also agree to make future revenue sharing payments to Lilly in an amount equal to 15 percent of global net sales of exenatide products until Amylin has made aggregate payments to Lilly of $1.2 billion plus accrued interest.

Amylin will issue a secured note in the amount of $1.2 billion to Lilly under which any revenue sharing payments made to Lilly will reduce amounts outstanding under the note.

If Amylin's investigational once weekly version of exenatide, BYDUREON (exenatide extended-release for injectable suspension), has not received U.S. Food and Drug Administration (FDA) approval prior to June 30, 2014, Amylin's revenue sharing obligations will terminate, and Amylin shall thereafter pay Lilly 8 percent of global net sales of exenatide products.

Amylin will also pay a $150 million milestone to Lilly contingent upon FDA approval of a once monthly suspension version of exenatide that is currently in Phase 2.

The companies have also agreed that the maturity date for the $165 million line of credit that Amylin drew from Lilly earlier in the year will be extended from the second quarter of 2014 to the second quarter of 2016.

Exclusive worldwide licensing agreement that will add two distinct nucleotide analogues to Vertex’s hepatitis C portfolio.

The compounds, which were discovered by Alios and are known as ALS-2200 and ALS-2158, have shown in in vitro studies to be potent inhibitors of the hepatitis C virus (HCV) polymerase, an enzyme essential for replication of the virus.

The addition of these compounds provides Vertex with multiple opportunities to develop potential, new, all-oral combination regimens for chronic hepatitis C.

Vertex expects ALS-2200 and ALS-2158 to enter clinical development later this year.

Alios will receive a $60 million up-front payment from Vertex for the worldwide rights to ALS-2200 and ALS-2158.

Vertex is responsible for development costs related to ALS-2200 and ALS-2158 and will also provide research funding to Alios.

In addition, Alios would be eligible to receive research and development milestone payments up to $715 million if both compounds are approved.

Vertex expects to pay approximately $35 million in development milestones in 2011.

Alios is also eligible to receive up to $750 million in sales milestones on sales of all approved medicines under the collaboration.

The agreement also includes tiered royalties on product sales.

As part of this agreement, Vertex gains worldwide rights to both compounds, further enabling the company to potentially expand development and commercialization efforts in hepatitis C to areas outside North America over the coming years.

The agreement also includes a research program that will focus on the discovery of additional nucleotide analogues that act on the hepatitis C polymerase.

Vertex will have the option to select compounds for development emerging from the research program.

Alios and Vertex plan to initiate clinical development of each compound in the fourth quarter of 2011, which is expected to include studies of the compounds in healthy volunteers followed by short-duration safety and viral kinetic studies in people with hepatitis C.

The goal of the first clinical studies of these compounds is to generate data to enable the initiation of Phase 2 studies as early as the end of 2012.

These Phase 2 studies are expected to evaluate multiple combination regimens of ALS-2200, ALS-2158, INCIVEK and VX-222.

The combination studies would be designed to generate sustained viral response (SVR or viral cure) data.

Additional details on the clinical development program for ALS-2200 and ALS-2158 will be provided later in 2011 upon initiation of the first clinical study.

Worldwide agreement outside of Asia to develop and commercialize tivozanib, AVEO's lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, for the treatment of a broad range of cancers.

AVEO will receive an initial cash payment of $125 million, composed of a $75 million license fee and $50 million in research and development funding.

AVEO is also eligible to receive approximately $1.3 billion in potential milestones comprised of $575 million in clinical and regulatory milestones, including $90 million in connection with the regulatory filings and market approval of tivozanib in RCC, as well as more than $780 million in commercial milestones.

Subject to regulatory approval, AVEO will lead commercialization of tivozanib in North America and Astellas will lead commercialization of tivozanib in the European Union (EU).

The companies will share equally all North American and EU development and commercialization costs and profits for tivozanib.

Outside of North America and EU, Astellas will be responsible for the development and commercialization costs of tivozanib and will be obligated to pay AVEO a tiered, double-digit royalty on sales in those territories.

Pursuant to the terms of a licensing agreement between Kyowa Hakko Kirin and AVEO, Kyowa Hakko Kirin retains the rights to develop and commercialize tivozanib in Asia.

AVEO will be responsible for the manufacturing of tivozanib.

Award to supply the U.S. government with 44.75 million doses of BioThrax (Anthrax Vaccine Adsorbed) over a period of five years for a total value of up to $1.25 billion.

Collaboration agreement with Amgen for the research of BiTE antibodies against three undisclosed solid tumor targets.

Amgen will have the right to pursue development and commercialization of BiTE antibodies against up to two of these targets, to be selected by Amgen.

Amgen is expected to pay €10 million upon deal execution.

If milestones in multiple indications and tumor types are achieved, Micromet is eligible to receive up to €342 million in clinical and commercial milestone payments.

Micromet is also eligible to receive up to double-digit royalties on worldwide net sales.

For the second BiTE program, Micromet is eligible to receive an additional cash payment upon initiation of the program, milestones, royalties and development funding comparable to the first program.

The combined potential payments to Micromet from both programs, excluding reimbursement of research and development costs, are approximately €695 million.

The initial development plan contemplates €25 million in funding of Micromet R&D activities if two BiTE antibodies are advanced to IND. All expected costs associated with the research, development and commercialization of the BiTE antibodies will be borne by Amgen.

Micromet will be primarily responsible for the discovery and pre-clinical development of the BiTE antibodies.

Amgen will lead the clinical development, manufacturing, and commercialization of any products resulting from the collaboration.

Agreement for advancing the research, development and commercialization of three drug candidates, including two of miRagen’s lead programs (miR-208 and miR-15/195) and one additional target yet to be identified, for cardiovascular disease.

This partnership provides worldwide rights, excluding the U.S. and Japan, to Servier.

Miragen will receive up to $45 million in total upfront, research support and near-term milestone payments over the next three years, as well as royalties on sales, based on the successful outcome of the collaboration.

Additional clinical and commercial milestones, as well as clinical development support for the successful development of the three compounds, would value the deal at approximately $1 billion.

Miragen and Servier will collaborate on the research and development effort, while Servier alone will be responsible for all costs associated with the global development, regulatory approval and commercialization of the three product candidates worldwide, excluding the U.S. and Japanese markets.

Miragen retains all rights in the U.S. and Japan, and the option to co-sponsor any Phase III programs in the event that Miragen, alone or together with a partner, should seek marketing approvals for any of the targets in the U.S. and Japan.

Agreement with Pharmacyclics to jointly develop and market the anti-cancer compound, PCI-32765.

A number of Phase 1 and 2 studies with PCI-32765 are ongoing across a panel of B-cell malignancy disorders, including chronic lymphocytic leukemia, mantle cell lymphoma, and diffuse large B-cell lymphoma.

The companies have entered into a worldwide 50/50 profit-loss agreement, sharing development and commercialization activities.

Janssen has made an upfront payment of $150 million which will be recorded in the fourth quarter, and will make additional payments based upon the achievement of certain development and regulatory milestones.

China Meheco has signed a two-year contract to provide 6.1 billion RMB ($939 million) of drugs to Venezuela.

Evotec and Roche have entered into an exclusive worldwide agreement for the development and commercialization of Evotec's MAO-B inhibitor in patients with Alzheimer's disease (AD).

Roche will pay Evotec an upfront fee of $10 million.

Evotec could receive further development and commercial milestone payments of up to $820 million as well as tiered double-digit royalties on sales.

Roche will initiate studies in 2012 to demonstrate proof of concept and will be responsible for all clinical development, manufacturing and commercialization activities.

Molecular Partners has entered into a strategic research collaboration and option agreement with Janssen Biotech to research, discover and develop DARPin products for the treatment of immunological diseases.

The collaboration and expansion of its current agreement with the company and its affiliates aims to explore a defined set of targets, including the use of multispecific DARPins, to address diseases where continued unmet needs for effective treatment options continue to exist.

Molecular Partners and Janssen Biotech will collaborate on research of DARPins to selected targets.

During the research phase, Janssen Biotech has the right to exercise four options to exclusively license DARPin-based products.

Upon execution of each option, Janssen Biotech will be solely responsible for all clinical development, manufacturing, and commercialization activities.

Molecular Partners has an option to co-develop one product on a global basis.

Molecular Partners will receive significant upfront fees, license payments and research funding as part of an innovative agreement, as well as development and sales milestones of up to $200 million for each option.

Upon commercialization, Molecular Partners will be entitled to a tiered and up to double-digit royalty on worldwide net sales.

Exclusive collaboration to develop and commercialize selective phosphodiesterase type 1 (PDE1) inhibitors, discovered by ITI, for the treatment of cognitive impairment associated with schizophrenia.

This agreement is targeted worldwide, but ITI has retained the option to co-promote with Takeda in the United States.

ITI will receive an upfront cash payment and will be eligible to receive payments of approximately $500 million in the aggregate upon achievement of certain development milestones and up to an additional $250 million in the aggregate upon achievement of certain sales-based milestones, along with tiered royalty payments based on net sales by Takeda.

Takeda will be solely responsible for development, manufacturing and commercialization of PDE1 inhibitors.

Exclusive global agreement to develop and commercialize a candidate biosimilar form of Enbrel (etanercept).

Hanwha Chemical Corporation, through its Bio Business Unit, and Merck, through a subsidiary, will work together to develop and commercialize HD203, a candidate biosimilar form of etanercept developed by Hanwha.

Merck will conduct clinical development and be responsible for manufacturing.

In addition, upon marketing approval, Merck will commercialize HD203 globally, except for in Korea and Turkey where Hanwha has retained marketing rights.

Hanwha receives an upfront payment from Merck and will be eligible for additional payments associated with milestones for technology transfer and regulatory progress as well as tiered royalties on sales.

Specific financial terms of the agreement were not disclosed.

Array BioPharma has announced an oncology agreement with Genentech for the development of each company's small-molecule Checkpoint kinase 1 (ChK-1) program.

The programs include Genentech's compound GDC-0425 (RG7602), currently in Phase 1, and Array's compound ARRY-575.

Genentech is responsible for all clinical development and commercialization activities.

Array will receive an upfront payment of $28 million and is eligible to receive clinical and commercial milestone payments up to $685 million and up to double-digit royalties on sales of any resulting drugs.

Full financial terms have not been disclosed.

Research, license and commercialisation agreement was signed with Merck Serono, a division of Merck KGaA, Darmstadt, Germany, for the discovery of new antibody-derived therapeutics against inflammatory disease targets using F-Star’s Modular Antibody Technology.

Merck Serono will nominate up to three therapeutic targets andthe parties will collaborate to jointly discover mono-specific Fc-based targeted biologics (Fcabs) and bi-specific IgG-based targeted biologics (mAb2) for which Merck KGaA will have exclusive worldwide development and commercialisation rights.

F-Star will receive an initial technology access fee and research-based funding and is eligible to receive additional license fees, development, regulatory and commercialisation milestones which in aggregate could reach €492 million, as well as undisclosed tiered royalties on product sales.

Further details of the agreement were not disclosed.

Prestige Brands announced the signing of a definitive agreements with GSK to acquire 17 over-the-counter (OTC) pharmaceutical brands sold in North America for a total of $660 million in cash.

Among the brands the Company agreed to acquire are the BC, Goody's, and Ecotrin brands of pain relievers; Beano, Gaviscon, Phazyme, Tagamet and Fiber Choice GI brands; and the Sominex sleep aid brand.

10 January 2011

Epizyme in worldwide strategic alliance with GlaxoSmithKline to discover, develop, and market novel small molecule therapeutics targeting histone methyltransferases (HMTs) for the treatment of cancer and other diseases.

Epizyme will receive an upfront payment of $20 million, as well as research funding.

Epizyme is eligible to receive more than $630 million in total milestone payments if medicines are commercialized for all targets in the collaboration.

Epizyme is eligible to receive up to double-digit royalties on net sales of products resulting from the alliance.

Epizyme will be primarily responsible for research up to development candidate selection, and GSK will be solely responsible for development and commercialization.

The collaboration will use Theraclone’s I-STAR technology to discover broadly protective monoclonal antibodies against up to four undisclosed targets in the areas of infectious disease and cancer.

Theraclone and Pfizer will embark on a discovery program to identify broadly reactive antibodies directed against up to two infectious disease targets and up to two cancer targets.

Pfizer will receive an exclusive worldwide license to any therapeutic antibodies discovered under the collaboration.

Theraclone is eligible to receive undisclosed royalties on sales of any developed products and up to $632 million in research funding and milestone payments upon the achievement of discovery, development, regulatory and commercialization milestones.

Pfizer will be responsible for preclinical and clinical development of the antibodies.

Agreement to grant Sanofi a license for the development andcommercialization of GBR 500, a novel monoclonal antibody for the treatment of Crohn’s Disease and other inflammatory conditions.

Glenmark will receive an upfront payment of US$ 50 million, of which US$ 25 million will be paid upon closing of the transaction and US$ 25 million, which is contingent upon Sanofi’s positive assessment of certain data to be provided by Glenmark.

Glenmark could receive potential success‐based development, regulatory and commercial milestone payments.

The total of these payments could reach US$613 Mn.

Glenmark is eligible to receive tiered double‐digit royalties on salesof products commercialized under the license.

Sanofi will have exclusive marketing rights for North America, Europe, Japan, Argentina, Chile and Uruguay.

Sanofi and Glenmark will comarket in Russia, Brazil, Australia and New Zealand, and Glenmark will retain exclusive marketing rights in India and other countries in the rest of the world.

Prosidion's patent estate and associated royalty stream relating to the use of dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes has been sold to Royalty Pharma for a total cash payment of USD 609 million.

The transaction is expected to close in July 2011.

Prosidion was acquired as part of Astellas' acquisition of OSI Pharmaceuticals in June 2010.

Royalty Pharma will be entitled to receive 100% of royalty payments and milestones related to the DPP-IV asset.

Additionally, Royalty Pharma will take over administration of the DPP-IV patent estate currently owned by Prosidion.

4 January 2011

XOMA and Servier to jointly develop and commercialize XOMA 052 in multiple indications.

XOMA will receive approximately $35 million upfront, up to approximately $470 million in milestone payments and tiered royalties up to a mid-teens percentage rate.

XOMA retains development and commercialization rights for Behcet's uveitis and other inflammatory and oncology indications in U.S. and Japan.

Servier receives similar rights in the rest of the world.

Servier will fund the first $50 million of XOMA 052 development expenses and 50% of further expenses for the Behcet's uveitis indication.

Servier will fund development for diabetes and cardiovascular disease indications in exchange for worldwide rights.

XOMA retains an option to reacquire the development and commercialization rights to the diabetes and cardiovascular indications in the U.S. and Japan by paying an option fee and partial reimbursement of incurred development expenses.

If XOMA reacquires these rights, it has the ability to license them to one or more third parties.

Exclusive license agreement with Centocor Ortho Biotech for the worldwide development and commercialization of AVEO’s internally-discovered antibodies targeting the RON (Recepteur d’Origine Nantais) receptor.

The RON pathway is believed to be involved in several aspects of cancer development including regulation of tumor growth, survival and metastasis, and bone disruption.

In preclinical studies, AVEO’s proprietary anti-RON antibodies have demonstrated strong anti-tumor activity.

AVEO is initially receiving $15 million.

AVEO will receive the first half of this amount as an up-front payment from Centocor Ortho Biotech.

Through a separate equity private placement and stock purchase agreement, the second half will be received through the sale of newly issued shares of AVEO common stock to an affiliate of Centocor Ortho Biotech, Johnson & Johnson Development Corporation.

AVEO is eligible to receive up to $540 million in milestone payments based upon the achievement of specified development, regulatory and commercialization goals.

Upon commercialization, AVEO will be entitled to a tiered, double-digit royalty on net sales worldwide.

Centocor Ortho Biotech will be responsible for all clinical development, manufacturing, and commercialization activities and costs.

Centocor Ortho Biotech will also fund certain research conducted by AVEO, including translational research studies using its Human Response Platform™ to identify biomarkers for patients most likely to benefit from treatment with RON-targeted antibodies.

Exclusive, worldwide collaboration and license agreement under which both companies will develop and commercialize highly selective, novel oral Syk inhibitors for the treatment of various autoimmune and inflammatory diseases, including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).

The collaboration’s lead molecule, PRT062607, has been shown to be a highly potent and specific oral inhibitor of Syk in a broad panel of in vitro kinase and cellular assays and is currently in Phase 1 studies.

Results of the studies to date suggest the compound is well tolerated and has a profile suitable for once-daily dosing.

Biogen Idec will provide Portola with an upfront payment of $36 million in cash and purchase $9 million in Portola equity, with additional payments of up to $508.5 million based on the achievement of certain development and regulatory milestones.

Biogen Idec will lead the global development and commercialization efforts for the Syk inhibitor program in major indications such as rheumatoid arthritis and lupus, while Portola will lead U.S. development and commercialization efforts for select smaller indications as well as discovery efforts for follow-on Syk inhibitors.

Portola retains an option to co-promote alongside Biogen Idec in the United States in major indications.

Worldwide costs and profits will be split by Biogen and Portola 75 percent and 25 percent, respectively.

17 February 2012

Pfizer and Zhejiang Hisun Pharmaceutical signed a framework agreement, advancing their previously announced memorandum of understanding (MOU) to establish a joint venture to develop, manufacture and commercialize off-patent pharmaceutical products in China and global markets.

The framework agreement builds upon the MOU, and is an important milestone in the formation of a joint venture between the two companies.

This potential partnership would aim to strengthen the ability of both companies to reach more patients with high-quality medicines in the branded generics arena.

According to the framework agreement, the potential joint venture will be named “Hisun Pfizer Pharmaceutical Co., Ltd.” Hisun will own 51% and Pfizer will own 49%, and the aggregate investment and registered capital will be USD 295 million and USD 250 million respectively.

Both parties could contribute selected existing products, manufacturing sites, cash and other relevant assets after the joint venture is formed.

The potential joint venture is subject to the satisfaction of certain closing conditions, including approval of relevant government authorities in China.

12 June 2011

Memorandum of understanding (MOU) on their intention to establish a joint venture.

This potential partnership would aim to strengthen the ability of both companies to reach more patients with high-quality and low-cost medicines in the branded generics arena.

Under the MOU, the two companies will explore a potential business collaboration focused on manufacturing cooperation to deliver high-quality medicines, broader commercialization of medicines through a local and global sales and marketing infrastructure and research and development of off-patent medicines.

Both parties could contribute select existing products and other relevant assets and capabilities to provide a solid platform for this potential joint venture.

Definitive agreement to acquire substantially all of the assets of Paddock Laboratories for approximately $540 million in cash.

Perrigo expects to receive a significant tax benefit as a result of the acquisition of Paddock's assets.

The net present value of this tax benefit is estimated to be $95 million.

The acquisition is expected to close during the Company's fiscal 2011 fourth quarter pending regulatory approval.

Exclusive global licence and collaboration agreement for dual-acting glucagon and GLP-1 receptor agonists for the treatment of patients with Type-2 diabetes and patients with obesity.

As part of the agreement, Boehringer Ingelheim obtains global development and commercialisation rights to ZP2929, Zealand Pharma's lead glucagon/GLP-1 dual agonist drug candidate.

Zealand Pharma will be responsible for conducting the first Phase I study with ZP2929 and Boehringer Ingelheim will fund the research, development and commercialisation of products under the agreement.

Depending on the achievement of pre-defined development, regulatory and commercial milestones, Zealand Pharma is eligible to receive payments for ZP2929 and may also receive additional milestone payments if other products covered by the collaboration are advanced through development.

Further, Zealand Pharma is entitled to tiered royalties that range from high single to low double digits on global sales of products under the agreement. Zealand Pharma retains co-promotion rights in Scandinavia.

During the first two years of collaboration, Zealand Pharma is eligible to receive signature, milestone, and other payments of up to 41 million including cost reimbursements and including research funding of up to 4 million.

In their research collaboration, Zealand Pharma and Boehringer Ingelheim will focus on the characterization, identification and development of additional glucagon/GLP-1 dual agonists for the exploration of new indications, formulations and delivery systems.

6 January 2011

Amgen and Xencor will collaborate to develop XmAb®5871, an Fc- engineered monoclonal antibody dually targeting CD19 and CD32b.

Amgen has the option to an exclusive worldwide license following the completion of a pre-defined Phase 2 study.

Xencor will lead all clinical development until that time.

Xencor will receive an up-front and early development milestone payments.

If Amgen does exercise its option, Amgen will assume responsibility for future development, Xencor will receive an option-exercise fee which, combined with the up-front and early development milestones, will total $75 million, and Xencor could receive up to an additional $425 million in clinical, regulatory and commercialization milestone payments.

Xencor will receive tiered royalties on future sales of XmAb5871.

HHS to make an award to SIGA of a contract to deliver 1.7 million courses of its smallpox antiviral for the Strategic National Stockpile

The contract is based ST-246® drug

The award relates to a Request for Proposal issued by HHS's Biomedical Advanced Research and Development Authority (RFP-BARDA-09-35).

The base contract, if finalized, is expected to generate revenues of approximately $500 million, and the entire contract, if all options are exercised, is expected to generate revenues of approximately $2.8 billion.

30 September 2010

Covance to become sanofi-aventis' R&D partner.

Over the next ten years, Covance expects to provide drug development services to sanofi-aventis, with estimated payments ranging from approximately $1.2 billion to $2.2 billion.

sanofi-aventis will utilize Covance's global R&D portfolio of discovery support, toxicology, chemistry, clinical Phase I IV, central laboratory, and market access services with annual commitments for these services increasing over the next decade.

These agreements include a 10-year sole-source relationship for central laboratory services.

26 October 2010

Boehringer Ingelheim and MacroGenics have entered into a global alliance to discover, develop and commercialize antibody-based therapeutics which may span multiple therapeutic areas, including immunology, oncology, respiratory, cardiometabolic and infectious diseases.

These developmental drug candidates will be based on MacroGenics' Dual-Affinity Re-Targeting (DART™) platform and will be directed against up to ten combinations of molecular targets.

Both companies will share responsibility for discovery and certain preclinical activities.

Boehringer Ingelheim will have sole responsibility for all subsequent preclinical, clinical, regulatory, commercial and manufacturing activities for any DART-based product resulting from the collaboration.

During the first three years of the collaboration, MacroGenics expects to receive payments of about $60 million, which includes an upfront cash payment, annual maintenance fees, R&D funding, and near-term research-based milestones.

Boehringer Ingelheim also expects to make a future equity investment in MacroGenics.

MacroGenics may be eligible to receive development, regulatory and commercial milestone payments that can reach up to $210 million for each of the ten DART programs in case of full commercial success of multiple DART products.

MacroGenics may also receive tiered royalties on net product sales.

MacroGenics has the option to co-promote certain DART products in the United States.

Further financial details were not disclosed.

7 December 2010

Cephalon and Mesoblast have entered into a strategic alliance to develop and commercialize novel adult Mesenchymal Precursor Stem Cell (MPC) therapeutics for degenerative conditions of the cardiovascular and central nervous systems.

These conditions include Congestive Heart Failure, Acute Myocardial Infarction, Parkinson's Disease, and Alzheimer's Disease. The alliance also extends to products for augmenting hematopoietic stem cell transplantation in cancer patients.

Cephalon will make an upfront payment to Mesoblast totaling US$130 million (US$30 million upon Mesoblast shareholder approval) and regulatory milestone payments of up to US$1.7 billion.

Mesoblast will be responsible for the conduct and expenses of certain Phase IIa clinical trials and commercial supply of the products.

Cephalon will be responsible for the conduct and expenses of all Phase IIb and III clinical trials and subsequent commercialization of the products.

Mesoblast will retain all manufacturing rights and will share significantly in the net product sales.

Under the terms of a Stock Purchase Agreement and a Subscription Deed, Cephalon will make an equity investment to purchase a 19.99% stake in Mesoblast at A$4.35 per share, totaling approximately US$220 million.

Bayer Schering Pharma AG and OncoMed Pharma announced a global strategic alliance to discover, develop and commercialize novel anti-cancer stem cell therapeutics targeting the Wnt signaling pathway.

The strategic alliance provides Bayer with the option to exclusively license antibody and protein therapeutic product candidates at any point up to the completion of Phase I testing.

In addition, Bayer and OncoMed will share technology and know-how to discover and develop small molecule inhibitors of the pathway.

Bayer and OncoMed will develop antibodies, protein therapeutics, and small molecules as potential novel anti-cancer stem cell therapeutics targeting the Wnt signaling pathway.

In addition to an upfront payment of $40 million, OncoMed is eligible to receive cash payments for product candidates that Bayer options and possible additional payments upon achievement of certain development and commercialization milestones.

The collaboration could potentially include up to five compounds.

The agreement includes potential significant near-term milestone payments from Bayer.

OncoMed's payments for each biotherapeutic or small molecule drug candidate successfully developed through Phase III clinical trials and regulatory approval, could total up to $387.5 million (biotherapeutic drug) and $112 million (small molecule drug) per program, already including net sales milestones.

1 February 2010

Agreement with Boston Scientific resolving two Delaware litigations related to Cordis's Palmaz and Gray patents and Boston Scientific's Jang patents.

Cordis will receive $1.725 billion from Boston Scientific and Johnson & Johnson expects to record the majority of this payment as a special item in the first quarter of 2010.

Boston Scientific will pay Cordis $1 billion by close of business today (Feb. 1, 2010) and $725 million on Jan. 3, 2011.

The disputes involved several coronary stent products including Cordis's Cypher stent and Boston Scientific's Liberte, Taxus Liberte and Taxus Express stents.

22 November 2010

f-star signed a collaboration and license agreement with Boehringer Ingelheim for joint discovery of new antibody-derived therapeutic products based on f-star’s Modular Antibody Technology.

Boehringer Ingelheim will nominate up to seven targets, which may span multiple therapeutic areas, against which the parties will collaborate to jointly discover Fcabs for further global development and commercialisation by Boehringer Ingelheim either as therapeutic products in their own right or as modules for the generation of bispecific mAb2 products.

f-star will receive an initial technology access fee, research-based funding, and is eligible to receive additional license fees, development, regulatory and commercial milestones and undisclosed tiered royalties on product sales.

Boehringer Ingelheim can select several therapeutic products from each of seven discovery programs whereas the total payment to f-star for each of these programs, excluding royalty payments, could reach up to Euro 180 million in case of full commercial success of multiple therapeutic products.

Further details of the agreement were not disclosed.

29 July 2010

Isis Pharma has earned a $5 million milestone payment from GSK related to the development of a candidate drug to treat an undisclosed rare and serious disease.

Isis will develop the drug to Phase 2 proof-of-concept, at which time GSK has the option to license it.

31 March 2010

Strategic agreement which covers up to six programs.

Isis will receive an upfront $35 million payment from GSK and is eligible to receive on average up to $20 million in milestones per program up to Phase 2 proof-of-concept.

GSK will have the option to license compounds at PoC, and will be responsible for all further development and commercialization.

Isis will be eligible to receive license fees and milestone payments, totaling nearly $1.5 billion, in the event all six programs are successfully developed for one or more indications and commercialized through to pre-agreed sales targets.

Isis will receive up to double-digit royalties on sales from any product that is successfully commercialized.

28 October 2010

Stryker Corp will buy Boston Scientific Corp's business that makes devices used to treat stroke, aneurysm and other vascular conditions in the brain for $1.5 billion in cash to diversify its products as its orthopedics business slows.

The price includes $100 million of milestone payments.

The deal is expected to close before the end of the year.

15 December 2011

Kyowa Hakko Kirin has elected to advance its first collaborative therapeutic oncology candidate from the research stage into formal development studies, triggering a $5 million milestone payment for Dicerna.

KHK has exercised an option to bring a second oncology target into the collaboration.

7 December 2010

Dicerna and Kyowa Hakko Kirin have expanded of their ongoing research collaboration into the new therapeutic area of immunologic and inflammatory diseases.

In January 2010, the companies announced a research collaboration and license agreement worth up to $1.4 billion for the research, development and commercialization of DsiRNA pharmaceuticals and drug delivery systems for therapeutic targets in oncology.

Dicerna will receive a cash payment for exercise by Kyowa Hakko Kirin of an option to bring an additional target into the collaboration.

With this expanded collaboration, Dicerna will be actively working in the therapeutic areas of oncology, endocrinology, immunology and inflammation.

4 January 2010

Research collaboration and license agreement for the research, development and commercialization of drug delivery systems and DsiRNA pharmaceuticals for therapeutic targets in oncology.

Dicerna will receive $4 million in upfront cash payments including research funding, and up to $120 million in additional research funding, development and commercial milestones for exclusive rights to one target in the field of oncology.

According to the progress of the research collaboration, Kyowa Hakko Kirin and Dicerna may expand the scope of the collaboration by adding approximately up to 10 targets under similar terms and may broaden the therapeutic focus of the partnership.

Dicerna is entitled to royalty payments on sales from products for these targets.

Dicerna also has an option to equally co-promote and profit-share (50:50) in the United States for the initial target.

Expansion agreement - December 2010

Dicerna Kyowa Hakko Kirin announced the expansion of their ongoing research collaboration into the new therapeutic area of immunologic and inflammatory diseases.

In January 2010, the companies announced a research collaboration and license agreement worth up to $1.4 billion for the research, development and commercialization of DsiRNA pharmaceuticals and drug delivery systems for therapeutic targets in oncology.

Under the terms of the expanded agreement, Dicerna will receive a cash payment for exercise by Kyowa Hakko Kirin of an option to bring an additional target into the collaboration.

With this expanded collaboration, Dicerna will be actively working in the therapeutic areas of oncology, endocrinology, immunology and inflammation.

31 December 2010

CVS Caremark will acquire the Medicare Prescription Drug business of Universal American.

CVS will acquire all of the outstanding stock of Universal American and concurrently distribute to Universal American shareholders 100% of the shares of a newly formed public company (“NewCo”), which will own all other operations of Universal American.

CVS will pay Universal American shareholders $1.25 billion plus the excess capital in the entities that operate the Medicare Prescription Drug business, estimated at $150 million, less Universal American’s outstanding debt and trust preferred securities, estimated at $340 million.

After payment of other transaction related expenses, Universal American shareholders are expected to receive approximately $12.80 per share to $13.00 per share in cash.

Universal American shareholders will receive one share of NewCo in exchange for each share of Universal American currently owned.

10 May 2012

Arena Pharmaceuticals and Eisai announced the expansion of the lorcaserin marketing and supply agreement between Arena Pharmaceuticals wholly owned subsidiary, Arena Pharmaceuticals, and Eisai.

Lorcaserin is an investigational drug candidate intended for weight management.

In addition to the United States, the territories in the expanded agreement now include most of North and South America, including Canada, Mexico and Brazil.

This expansion builds on the agreement executed by Eisai and Arena in July 2010 for Eisai's exclusive rights to market and distribute lorcaserin in the United States, subject to lorcaserin's approval by the US Food and Drug Administration (FDA).

1 July 2010

Eisai will market lorcaserin for obesity and weight management in the United States following FDA approval under the terms of a marketing and supply agreement between Arena Pharma and Eisai.

Arena has granted Eisai exclusive U.S. rights to commercialize lorcaserin.

Arena will manufacture lorcaserin at its facility in Switzerland and sell finished product to Eisai for marketing and distribution in the United States.

Arena will receive an upfront payment of $50 million from Eisai and, upon regulatory approval and the delivery of product supply for launch, up to an additional $90 million in milestone payments.

Arena will sell lorcaserin to Eisai for a purchase price starting at 31.5% of Eisai's annual net product sales, and the purchase price will increase on a tiered basis to as high as 36.5% on the portion of annual net product sales exceeding $750 million.

Arena is also eligible to receive $1.16 billion in one-time purchase price adjustment payments based on annual sales levels of lorcaserin and up to an additional $70 million in regulatory and development milestone payments.

17 February 2010

Exclusive worldwide license agreement for the global development and commercialization of fostamatinib disodium (R788) for rheumatoid arthritis (RA) and additional indications.

AstraZeneca will make an upfront payment to Rigel of $100 million with up to an additional $345 million payable if specified development, regulatory and first commercial sale milestones are achieved.

Rigel will also be eligible to receive up to an additional $800 million of specified sales related milestone payments if the product achieves considerable levels of commercial success, as well as significant stepped double-digit royalties on net sales worldwide.

AstraZeneca is responsible for all development, regulatory filings, manufacturing and global commercialization activities in all licensed indications under the contract.

AstraZeneca will design a global phase 3 program, anticipated to begin in the second half of 2010, with the goal of filing new drug applications with the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) in 2013.

AstraZeneca will also receive exclusive rights to Rigel's portfolio of oral Syk inhibitors, as well as for additional indications for fostamatinib disodium beyond RA.

16 November 2011

Roche will initiate a new program to expand its collaboration with Aileron to discover, develop and commercialize Stapled Peptide drugs.

Aileron and Roche will now commence work on a third program focused on inflammatory diseases.

24 August 2010

Aileron Therapeutics and Roche have a collaboration to discover, develop and commercialise a new class of drugs called Stapled Peptide Therapeutics.

Roche will work with Aileron to develop drug candidates against up to five targets which include oncology, virology, inflammation, metabolism and CNS.

Roche will provide Aileron guaranteed funding of at least $25 million in technology access fees and R&D support.

Aileron is eligible to receive up to $1.1 billion in payments upon the achievement of discovery, development, regulatory and commercialisation milestones, if drug candidates are developed against all five targets.

Aileron will receive royalties on future sales for any marketed products that result from the collaboration.

TransTech and Forest have entered into a license agreement for the development and commercialization of small molecule compounds discovered and developed by TransTech Pharma.

Through the license agreement, Forest will provide to TransTech Pharma an upfront license payment of $50 million.

TransTech Pharma could receive up to $1.105 billion in upfront and milestone payments for the successful development and commercialization of the GKA compounds.

Forest will also pay TransTech Pharma royalties on worldwide product sales and will be responsible for development and commercialization costs.

TransTech Pharma retains the rights to the Middle East and North Africa, while Forest receives exclusive rights to the rest of the worldwide market.

The portfolio licensed by Forest consists of a lead compound, TTP399, which has completed Phase I studies and other compounds in Phase I and pre-clinical stages of development.

2 September 2010

Orexigen and Takeda Pharma have an exclusive partnership to develop and commercialize Contrave® (naltrexone SR/bupropion SR) for treatment of obesity in the United States, Canada and Mexico.

Orexigen will receive an upfront cash payment of $50 million from Takeda.

Takeda will obtain an exclusive marketing right in the United States, Mexico and Canada.

Orexigen retains the right to co-promote with Takeda in the United States.

Orexigen will be eligible to receive payments of over $1 billion upon achieving certain regulatory and sales-based milestones.

Takeda will pay tiered double-digit royalty payments on net sales in the Territory.

Orexigen and Takeda will work together on ongoing development of the product, with Orexigen leading pre-approval activities, and Takeda leading post-approval activities.

The parties will share in the costs of any future development of the product.

Orexigen and Takeda will work together on ongoing development of the product, with Orexigen leading pre-approval activities, and Takeda leading post-approval activities.

The parties will share in the costs of any future development of the product.

22 March 2011

Merck and sanofi-aventis in mutual termination of agreement to form a new animal health joint venture by combining Merial, the animal health business of sanofi-aventis, with Intervet/Schering-Plough, Merck's animal health unit.

As a result, each party will keep its current, separate animal health assets and businesses.

9 March 2010

sanofi-aventis has exercised its option to combine Merial with Intervet/Schering-Plough, Merck’s Animal Health business, to create a global leader in Animal Health.

The new joint venture will be equally-owned by Merck and sanofi-aventis.

The formation of this new animal health joint venture is subject to execution of final agreements, antitrust review in the United States, Europe and other countries and other customary closing conditions.

The completion of the transaction is expected to occur in approximately the next 12 months.

The entreprise value of Merial has been fixed at $8 billion and the entreprise value of Intervet/Schering-Plough at $8.5 billion, leading to a true-up payment of $ 250 million to Merck to establish a 50/50 joint venture.

An additional amount of $750 million will be paid by sanofi-aventis, as per the terms of the agreement signed on July 29, 2009.

All payments, including adjustments for debt and certain other liabilities will be made upon closing of the transaction.

This new joint venture will offer a broader portfolio of animal health products and services in pharmaceuticals and biologics, as well as the ability to capitalize on growth opportunities in all fields and countries around the world.

Exclusive option agreement with Novartis for the development and commercialisation of Transgene’s targeted immunotherapy product, TG4010 (MVA-MUC1-IL2), for the first-line treatment of non-small cell lung cancer(NSCLC) and other potential cancer indications.

Pursuant to the agreement, Transgene has granted Novartis an option to acquire an exclusive worldwide license for TG4010 and Novartis will pay Transgene a $10 million non-refundable option fee.

Contingent upon the exercise of the option by Novartis and the achievement ofsuccessful development, regulatory and commercial milestones in various indications, Transgene is eligible to receive up to a total of approximately €700 million.

According to the agreement, Transgene will initially fund and retain control over the next clinical development phase of TG4010, which is a pivotal, global phase IIb/III clinical trial that Transgene currently anticipates starting by the end of 2010.

This study will involve approximately 1,000 patients with MUC1-positive NSCLC who have normal levels of activated Natural Killer (NK) cells at time of trial entry1.

The final results are expected to become available by the end of 2013.

Results from the phase IIb portion of this combined phase IIb/III clinical trial are expected to be available in the first quarter of 2012.

In accordance with the option agreement, Novartis will have up to 90 days after receiving results from Transgene for this phase IIb portion to exercise its option.

If the option is exercised:

• Novartis will assume all development, regulatory and commercialisation costsrelated to TG4010 across all indications.

• Transgene will receive a non-refundable licence issuance fee and furthermilestones contingent upon successful development for various indications andthe achievement of longer-term commercialisation targets.

• Transgene will receive royalties on global sales.

• Transgene will retain co-promotion rights in certain countries including France and China.

• Transgene will retain primary manufacturing rights for TG4010 to supplyNovartis’ clinical and commercial requirements.

Transgene and Novartis will now form a joint working group to oversee the implementation of the TG4010 global development program.

20 December 2010

Avila Therapeutics has signed a worldwide strategic alliance with sanofi-aventis to discover targeted covalent drugs for the treatment of cancers.

Sanofi-aventis obtains a worldwide exclusive license to develop and commercialize the compounds resulting from the discovery collaboration.

Sanofi-aventis will work together with Avila to design targeted covalent drugs directed towards six signaling proteins that are critical in tumor cells.

For the selected targets sanofi-aventis will have access to Avila’s proprietary Avilomics™ platform.

Avila has the opportunity to retain the rights to one of the six collaboration programs after the end of the initial three-year collaboration term and sanofi-aventis retains a right of first negotiation for such program should Avila decide to partner that program.

Avila will receive up to 40 million U.S. Dollars in upfront and research support payments, and is eligible to receive pre-clinical, clinical & regulatory milestone payments up to 154 million U.S. Dollars per collaboration program if the respective product is approved in the US, Europe and Japan.

Avila may also receive staged royalties and commercial milestones on product sales in each of the programs advanced by sanofi-aventis.

Definitive agreement to sell its global distribution business, known for many years as Ashland Distribution, to TPG Capital for $930 million.

13 September 2010

Asset purchase agreement under which Laboratory Corporation of America Holdings (LabCorp) will acquire Genzyme Genetics for $925 million in cash.

LabCorp will purchase the business in its entirety, including all testing services, technology, intellectual property rights, and its nine testing laboratories.

LabCorp is committed to offer employment to the unit’s approximately 1900 employees upon closing, including senior management.

16 August 2010

Aspen Pharmacare to buy the drugmaking arm of Sigma Pharma in a recrafted deal for $804 million cash.

This deal leaves Sigma with its drug distribution and pharmacy business.

11 January 2010

Global multi-year strategic alliance with Roche to develop potential new therapies in COPD (chronic obstructive pulmonary disease).

In the alliance, Galapagos will apply its target discovery platform to discover novel COPD targets.

Galapagos is then responsible for the discovery and development of new small molecule candidate drugs against these targets.

Roche will have an exclusive option to license each small molecule program after either clinical candidate selection or completion of Phase I clinical trials.

In addition, Roche has an exclusive option to license the COPD targets for the discovery and development of antibodies against these targets.

Upon exercise of each option, Roche will be responsible for the further (pre)clinical development and commercialization.

Galapagos has received a research access payment of €6 million from Roche.

Galapagos is also eligible to receive discovery, development, regulatory and sales milestone payments that could potentially exceed €400 million, plus royalties upon commercialization of any products covered in the agreement.

Expanded agreement - May 2010

Galapagos has expanded its multi-year strategic alliance with Roche to develop potential new therapies in COPD (chronic obstructive pulmonary disease).

The partners have increased the number of antibody targets in the alliance.

These targets can now also be used as starting points for molecules consisting of nucleic acids and/or amino acids.

The alliance expansion announced today has the potential to increase the total value of milestone payments Galapagos receives under this agreement by EUR150 million.

16 December 2010

Galapagos announced today that it has achieved EUR3.5 M in milestone payments in its strategic alliance with Roche.

The alliance was also broadened to include novel target and drug discovery in fibrosis.

Regulus and sanofi-aventis have entered into a global, strategic alliance to discover, develop, and commercialize microRNA therapeutics.

The alliance will initially focus on the therapeutic area of fibrosis. 

The alliance is valued at over $750 million, and includes a $25 million upfront fee, a $10 million future equity investment, and annual research support for three years with the option to extend two additional years.

Regulus also could receive preclinical milestones as well as development and sales milestones for collaboration targets.

Regulus is eligible to receive royalties on microRNA therapeutic products commercialized by sanofi-aventis.

sanofi-aventis will support 100% of the costs of clinical development and commercialization of each program.

Sanofi-Aventis also receives an option for a broader technology alliance that provides Regulus certain rights to participate in development and commercialization of resulting products.

If exercised, this three-year option is worth an additional $50 million to Regulus.

Regulus has certain opt-in rights to participate in the development and commercialization of future sanofi-aventis clinical microRNA programs. 

Regulus is eligible to receive milestone payments and royalties on microRNA therapeutic products developed and commercialized under the technology alliance option.

12 October 2010

Synosia has granted UCB a license for exclusive, worldwide rights to the development compound SYN-115 and rights to a second compound, SYN-118, for non-orphan indications.

Both are in Phase II clinical development for the treatment of Parkinson’s disease.

UCB will make an equity investment totalling USD 20 million as part of a Series C funding in Synosia.

Synosia will also receive an undisclosed upfront payment and could receive potential regulatory and commercial milestone payments of up to a total of USD 725 million across both compounds.

Reflecting the strategic nature of the alliance, two representatives of UCB will join Synosia’s Board of Directors.

Synosia will be responsible for SYN-115 and SYN-118 through Phase II clinical development.

UCB will be responsible for Phase III clinical development and commercialisation.

The agreement also allows for additional compounds from either company’s pipeline to be brought into the collaboration on terms to be negotiated.

As with SYN-115 and SYN-118, Synosia will be responsible for the development of any additional molecules up to the end of Phase II.

9 November 2010

Tyco International has entered into an agreement to sell a 51% stake in its Electrical and Metal Products business to the private equity firm Clayton Dubilier & Rice.

Tyco will receive total cash proceeds of approximately $720 million and will use these proceeds to accelerate share repurchases under a $1 billion program announced by the company on September 8, 2010.

The transaction will result in the following:

A CD&R-managed fund will contribute $306 million for a 51% preferred interest and Atkore will obtain $465 million in third-party financing.

Tyco will recognize a gain on the transaction of approximately $200 million with a minimal tax liability.

Cellzome has strategic alliance with GlaxoSmithKline (GSK).

This gives GSK exclusive access to Cellzome’s proprietary Episphere™ technology in the emerging field of epigenetics as applied to immunoinflammatory disease.

The companies will work together using Cellzome’s Episphere™ technology platform, to identify selective small-molecule drug candidates against targets from four different epigenetic target classes.

The companies will share operational responsibility for the programs until identification of drug candidates, at which stage GSK will assume responsibility for any further preclinical and clinical development and commercialisation.

Cellzome will receive an upfront payment of €33 million, comprising technology access fees and the purchase of equity.

In addition, Cellzome is eligible for milestone payments and tiered royalties for each programme.

Milestone payments under this collaboration could reach over €475 million if all programmes under the alliance are successfully developed and commercialised.

18 August 2010

Quark has granted Novartis an option to obtain an exclusive worldwide license to develop and commercialize its p53 temporary inhibitor siRNA drug QPI-1002, currently the subject of a Phase II clinical trial.

Quark will receive initially a non-refundable fee of 10 million USD.

In the event that Novartis exercises the option, Quark would receive option exercise fees and milestone payments that could potentially total 670 million USD.

In addition Quark would be entitled to potential royalties on sales of licensed products.

AstraZeneca will exercise the option to obtain Merck's interest in AstraZeneca's non-proton pump inhibitor (non-PPI) products this year.

Those products are Atacand™, Lexxel™, Plendil™ and Entocort™ plus certain products currently in clinical development.

In April, Merck will receive a payment of $647 million which represents the net present value as of March 31, 2008 for the company's share of the projected pretax revenue for the non-PPI products.

As a result of this decision, AstraZeneca will have an option to acquire Merck's interest in the PPI products, including Nexium™, in 2012, or later, under certain circumstances.

Roche and reMYND today have an agreement to develop novel therapeutics that could slow down neurodegeneration in Parkinson’s and Alzheimer’s patients.

reMYND could receive over half a billion Euros in milestone payments, additional FTE payments and royalties on resulting net sales, potentially reaching a double-digit level.

2 June 2011

Diamyd Medical has regained control of the diabetes therapy Diamyd following Ortho-McNeil-Janssen Pharmaceuticals election to terminate the agreement the two companies signed in June 2010 to develop and commercialize Diamyd.

The termination of the agreement follows the evaluation of the results of a European Phase III study with Diamyd reported on May 9.

The study did not meet the primary efficacy endpoint of preserving beta cell function at 15 months in patients newly diagnosed with type 1 diabetes, although a small positive effect was seen.

22 June 2010

Diamyd has an agreement with Ortho-McNeil-Janssen Pharmaceuticals (OMJPI)to develop and commercialize the Diamyd(R) diabetes therapy.

The agreement relates to the development and world-wide commercialization of the GAD65 antigen-based therapy (Diamyd(R).

OMJPI will make an upfront payment of $45 million.

Diamyd could receive additional development and sales milestone payments of up to $580 million, as well as tiered royalties on future sales.

The parties will equally share costs for the development program until results from the ongoing EU phase III study, expected in the first half of 2011.

OMJPI has the right to fully assume responsibility for the development program upon reviewing the results.

Diamyd has secured exclusive rights for commercialization in the Nordic countries.

Diamyd also retains the rights to the therapeutic use of the GAD65 gene and derivatives fragments and variants of the GAD65 protein.

17 March 2011

Elected to exercise its option with Merck & Co., Inc., to co-promote ridaforolimus, an investigational mTOR inhibitor, in the sarcoma indication upon its potential approval in the United States next year.

Based on the terms of the license agreement that ARIAD and Merck entered into in May 2010 for the development, manufacture and commercialization of ridaforolimus in oncology, ARIAD has the option to co-promote ridaforolimus with up to 20 percent of the sales effort for the product in all indications in the U.S., and Merck will compensate ARIAD for its sales efforts.

4 May 2010

ARIAD has granted Merck an exclusive license to develop, manufacture and commercialize ridaforolimus in oncology, and Merck will assume responsibility for all ridaforolimus activities, including clinical trials and regulatory filings.

Both companies had previously shared co-exclusive rights.

Merck will make an upfront cash payment of $50 million to ARIAD and will reimburse ARIAD for its ridaforolimus expenses incurred since January 1, 2010, estimated by ARIAD to be approximately $19 million.

Merck will also fund 100 percent of future ridaforolimus development, manufacturing and commercialization costs, effective immediately.

ARIAD will be eligible to receive up to $514 million in regulatory and sales milestones based on the successful development and commercialization of ridaforolimus in multiple indications.

This includes $65 million in milestones associated with the potential sarcoma indication, which currently is in Phase 3 clinical development (i.e., $25 million for acceptance of the new drug application by the FDA, $25 million for U.S. marketing approval, $10 million for European marketing approval, and $5 million for Japanese marketing approval), and $200 million in milestones based on achievement of significant sales thresholds.

Merck will book global sales of ridaforolimus and pay ARIAD tiered double-digit royalties on global net sales of ridaforolimus.

In addition to now receiving royalties on U.S. sales in lieu of a profit split, these global royalty rates are approximately one-third greater than the royalty rates that ARIAD would have received for ex-U.S. sales under the original collaboration agreement with Merck.

ARIAD will have an option to co-promote ridaforolimus with up to 20 percent of the sales effort for the product in all indications in the U.S., and Merck will compensate ARIAD for its ridaforolimus sales efforts.

ARIAD will transition all ridaforolimus activities to Merck, which ARIAD estimates will be completed within six months.

Merck will reimburse ARIAD for 100 percent of its ridaforolimus costs incurred until the transition is completed.

Milestones associated with the start of four Phase 3 clinical trials ($74.5 million) in indications other than sarcoma and the development-cost advance contemplated by the original collaboration agreement are not included in the revised agreement, since Merck will be responsible for fully funding all clinical trials and other development activities.

The terms for development and commercialization of ridaforolimus in potential non-oncology indications remain subject to future agreement between the companies.

31 January 2012

Orexo and Janssen Pharmaceuticals and Janssen Pharmaceutica have decided to end their research collaboration and license agreement regarding the OX-CLI and OX-ESI programs and a third, undisclosed Janssen program.

Each party has regained all commercial rights for its respective drug discovery programs.

Hence, the OX-CLI and OX-ESI programs, focusing on discovering and developing innovative new treatments for asthma, chronic obstructive pulmonary disease and other inflammatory diseases, will be closed.

1 June 2010

Research and development alliance and license agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica NV (collectively “OMJ”).

The licenses granted to OMJ under the agreement include worldwide licenses to Orexo’s ongoing OX-CLI and OX-ESI programs focusing on discovering and developing innovative small-molecule treatments for asthma, chronic obstructive pulmonary disease, and other inflammatory diseases.

In addition, OMJ will add a third internal program focusing on discovering and developing innovative small-molecules against an undisclosed target to the alliance on the same financial terms.

Initially, the agreement will run for three years, with an option for OMJ to extend the alliance and funding.

To Orexo, the alliance will bring a research funding contribution of up to USD 21.5 million (SEK 167 million) over the first three years, including an upfront payment of USD 10 million (SEK 77.8 million).

Upon the successful development and commercialization of all three initial alliance programs for multiple indications, Orexo will be entitled to total development milestone payments of up to USD 564 million (SEK 4,390 million), plus additional sales milestones for each program.

Commercialized products will also provide royalties.

In addition, the agreement grants Orexo an option for rights to co-promote drugs from the programs marketed by OMJ in Nordic and Baltic countries.

OMJ will be responsible for all clinical development and commercialization activities, including costs.

The alliance will leverage Orexo’s world-leading expertise in the arachidonic acid field and its two advanced pre-clinical programs aimed at developing powerful new drugs in the fight against serious respiratory illnesses.

16 June 2010

Abbott and Neurocrine Biosciences have entered into a collaboration agreement to develop and commercialize elagolix for the treatment of endometriosis-related pain.

In addition to endometriosis, elagolix will be evaluated for the treatment of uterine fibroids

Abbott will receive worldwide exclusive rights to develop and commercialize elagolix and all next-generation GnRH antagonists for women's and men's health.

Abbott will make an upfront payment of $75 million and will fund all ongoing development activities.

Neurocrine is eligible to receive additional milestone payments of approximately $500 million from Abbott for the achievement of certain development, regulatory and commercial milestones; funding for certain internal collaboration expenses; plus royalty payments on any future product sales.

18 August 2010

Owens & Minor has won three Department of Defense contracts worth a total of $547.2 million for medical supplies and services.

The work on all three contracts is scheduled to be complete in April 2012.

30 August 2011

Strategic partnership agreement, to create a European hemophilia commercial organization, to launch Inspiration’s hemophilia product portfolio in Europe.

This partnership is designed to leverage the combined strengths of Ipsen’s well established European commercial infrastructure and medical network, with Inspiration’s expertise in the field of hemophilia.

Inspiration and Ipsen will work together to hire and train a highly specialized commercial team to serve as the exclusive sales organization in Europe for all hemophilia drugs commercialized under the Inspiration brand.

This commercial organization will take the form of a hemophilia business unit nested within Ipsen’s existing commercial organization.

The hemophilia business unit will act as the exclusive commercial agent for all Inspiration products sold in the European Union, Russia and other European countries (in a total of 53 countries).

Sales in the business unit will be booked by Inspiration.

Ipsen will book all related sales and marketing expenses, rebill them to Inspiration and record them in Other Revenues.

Additional financial terms of the agreement were not disclosed.

21 January 2010

Partnership to create a world leading hemophilia franchise.

The partnership is designed to leverage combined expertise and resources to advance a broad portfolio of recombinant proteins, which address all major hemophilia disorders in a unique way by focusing on two significant unmet needs: wider access to treatment with coagulation factors and treatment for inhibitor complications.

The two lead product candidates are scheduled to begin Phase III clinical testing in 2010 including Ipsen’s recombinant porcine factor VIII, OBI-1 (for the treatment of patients with acquired hemophilia and hemophilia A who have developed an inhibitory immune reaction to human forms of factor VIII), and Inspiration’s recombinant factor IX product, IB1001 (for the acute and preventative treatment of bleeding in patients with hemophilia B).

Combined with Inspiration’s novel proprietary technology and an early-stage pipeline of additional hemophilia factors, this broad and unique portfolio would provide greater access to care and fulfill unmet needs for patients suffering from bleeding disorders.

Ipsen will exclusively sub-license OBI-1 to Inspiration in exchange for $50 million in convertible notes and a 27.5% royalty on future OBI-1 sales.

Inspiration will also enter a separate agreement with Ipsen for supply of the OBI-1 product.

Ipsen will provide up to $259 million of funding to Inspiration.

The proceeds will be used for the development and commercialization of its hemophilia pipeline, including OBI-1.

Ipsen will make an upfront investment of $85 million in Inspiration in exchange for shares of a new class of preferred stock constituting 20% of Inspiration’s fully-diluted equity.

In connection with the agreement, Ipsen will be entitled to appoint one member (out of a total of 7) to the Board of Directors of Inspiration.

In addition, milestone payments up to $174 million would be paid to Inspiration based on the successful development of IB1001 and OBI-1.

For each milestone payment, Ipsen would receive a note convertible into Inspiration equity with a 7- or up to 9-year maturity and a 2.5% coupon.

These notes would be redeemable in cash at maturity at Ipsen’s discretion.

Assuming all milestones payments are made, and the notes are converted into Inspiration equity, Ipsen would hold approximately 47% of Inspiration’s equity on a fully diluted basis.

Upon certain triggering events, Ipsen would also have the ability to acquire full control of Inspiration.

The transaction is expected to close in the first quarter of 2010.

License, co-development and co-promotion agreement with Astellas Pharma for azole antifungal agent isavuconazole in phase III clinical development for the treatment of life-threatening invasive fungal infections on a worldwide basis, including an option for Japan.

Basilea will receive an upfront payment of CHF 75 million and will be eligible to receive up to CHF 478 million in additional payments on achievement of pre-specified development and sales milestones.

Basilea will also receive significant double-digit tiered royalties on sales.

Astellas is granted an exclusive right to commercialize isavuconazole whereas Basilea retains an option to co-promote the product in the United States, Canada, major European countries and the People's Republic of China.

Basilea and Astellas will jointly participate in the development of isavuconazole.

Astellas will lead the development and contribute the majority of the investments required for completing the clinical development program investigating isavuconazole in the treatment of patients with invasive fungal infections caused by Aspergillus or other filamentous fungi (mold infections) and Candida fungi (yeast infections).

Basilea will initially manage.

Astellas has the right to take over the management of manufacturing and will bear manufacturing costs for commercial supply and commercialization costs.

20 December 2010

Lpath has entered into an agreement providing Pfizer with an exclusive option for a worldwide license to develop and commercialize iSONEPTM for the treatment of wet age-related macular degeneration (wet AMD) and other ophthalmology disorders.

Pfizer will provide Lpath with an upfront option payment of $14 million in addition to sharing the cost of the planned Phase 1b and Phase 2a trials.

Pfizer has the right to exercise its option for worldwide rights to iSONEP for an undisclosed option fee and, if Pfizer exercises its option, Lpath will be eligible to receive development, regulatory and commercial milestone payments that could total up to $497.5 million.

Lpath will be entitled to receive tiered double-digit royalties based on sales of iSONEP.

Lpath has granted to Pfizer a time-limited right of first refusal for ASONEPTM, Lpath's product candidate that is being evaluated for the treatment of cancer.

Two Phase 2a trials are currently planned to further assess ASONEP's efficacy and safety in cancer patients.

4 August 2010

Amplimmune has a broad strategic alliance with GSK to further develop PD-1 targeting therapies that may be effective in the treatment of cancer and other diseases.

GSK will obtain exclusive worldwide rights to AMP-224 as well as other potential next generation fusion proteins that target PD-1.

Under the terms of this agreement, GSK will pay Amplimmune a non-refundable upfront payment of $23 million. Amplimmune is eligible to receive up to $485 million in regulatory, development and sales milestone payments including milestones associated with IND filing and conducting a Phase 1 trial of AMP-224. Amplimmune may also receive up to double digit royalties on global sales.

31 August 2010

Agreed to sell its Illumination and Detection Solutions (IDS) business to Veritas Capital, for approximately $500 million in cash ($482 million net of payment for acquired cash balances).

Definitive agreement with the Solvay Group for Abbott to acquire Solvay's pharmaceuticals business for EUR 4.5 billion ($6.6 billion) in cash, providing Abbott with a large and complementary portfolio of pharmaceutical products and a significant presence in key global emerging markets.

The acquisition also includes full global rights to the fenofibrate franchise. Currently Abbott has U.S. rights to fenofibrate and pays royalties to Solvay.

30 July 2009

Companies have signed a definitive agreement under which Merck will sell its 50 percent interest in the companies' current animal health joint venture, Merial Limited (Merial), to sanofi-aventis for $4 billion (US) in cash.

Following the close of the transaction, sanofi-aventis will own 100 percent of Merial.

9 March 2010

Sanofi-aventis has exercised its option to combine Merial with Intervet/Schering-Plough, Merck’s Animal Health business, to create a global leader in Animal Health.

The new joint venture will be equally-owned by Merck and sanofi-aventis.

The completion of the transaction is expected to occur in approximately the next 12 months.

Payment of $250 million to Merck to establish a 50/50 joint venture.

An additional amount of $750 million will be paid by sanofi-aventis, as per the terms of the agreement signed on July 29, 2009.

All payments, including adjustments for debt and certain other liabilities will be made upon closing of the transaction.

Definitive agreement under which Express Scripts, one of the largest pharmacy benefits management (PBM) companies in North America, will acquire WellPoint's NextRx subsidiaries for $4.675 billion, which includes consideration for the value of a future tax benefit for Express Scripts based on the structure of the transaction.

The Procter & Gamble Company and Warner Chilcott plc today announced an agreement for the sale of P&G's global pharmaceuticals business to Warner Chilcott for an up-front cash payment of $3.1 billion.

30 October 2009

Warner Chilcott plc has completed the acquisition of The Procter & Gamble Company's global branded prescription pharmaceutical business.

To finance the acquisition, the Company used a combination of cash on hand and borrowings under new senior secured credit facilities.

The new senior secured credit facilities provided for $3.2 billion in financing and are comprised of;

$250 million revolving credit facility with a five-year maturity,

$1.0 billion Term Loan A with a five year maturity,

$1.6 billion Term Loan B with a five-and-a-half year maturity

$350 million delayed-draw Term Loan B with a five-and-a-half year maturity.

Borrowings under the Term Loan A and revolving credit facility bear interest at LIBOR plus 3.25% and under the Term Loan B and delayed-draw facility at LIBOR plus 3.50%, in all cases subject to a 2.25% floor on LIBOR.

At the closing, the Company borrowed a total of $2.6 billion under the term loan facilities and did not borrow under the revolving credit facility or the delayed-draw term loan facility.

The Company's existing $380 million aggregate principal amount of 8 3/4% senior subordinated notes remain outstanding.

Amended agreement - April 2010

Warner Chilcott and sanofi-aventis have announced an amendment to the Actonel global collaboration agreement with respect to the parties' arrangement in the United States and Puerto Rico.

Warner Chilcott will take full operational control over the promotion, marketing and R&D decisions for Actonel in the United States and Puerto Rico, and will assume responsibility for all associated costs relating to those activities.

Prior to the amendment, Warner Chilcott shared such costs with sanofi-aventis in these territories.

sanofi-aventis will receive collaboration payments from Warner Chilcott based on an agreed upon percentage of U.S. and PR net sales for the remainder of the term of the collaboration agreement, which expires at the end of 2014.

All other aspects of the global collaboration agreement remain in effect.

Termination agreement - September 2010

Warner Chilcott has agreed to terminate its existing co-promotion agreement with Novartis and signed a definitive agreement to purchase the U.S. rights to Enablex® from Novartis for $400 million in cash.

Bayer will continue to fund a portion of alemtuzumab’s development in MS and will retain an option to co-promote the product in MS upon approval.

In addition, Genzyme will assume sole responsibility for worldwide sales and marketing for Campath in B-cell chronic lymphocytic leukemia (CLL), where it is indicated for use as a single agent in first-line and previously-treated patients with this disease.

Bayer will retain the right to develop and commercialize alemtuzumab in solid organ transplant indications.

Genzyme will lead the development program.

Bayer, which has been co-developing alemtuzumab in MS with Genzyme, will continue to fund development at current levels until the investigational compound is approved for this indication.

After approval, Bayer will receive payments contingent on annual revenue until $1.25 billion in payments is realized.

The agreement includes a ten-year time cap on payments.

Bayer may also receive future milestone payments as a percentage of worldwide sales beginning in 2021 if Genzyme does not exercise a buyout option in 2020 for up to $900 million.

Genzyme will assume primary responsibility for the commercialization.

Bayer, which currently markets Betaseron® (interferon beta-1b) for MS, retains an option to co-promote alemtuzumab in MS. Oncology Drugs

For the oncology drugs Fludara, Leukine, and Campath/MabCampath, Bayer will receive payments contingent on annual revenue, capped at $500 million or eight years.

In addition, Bayer could receive $150 million in total milestone payments beginning in 2011 if certain annual revenues are met across a three-year time period.

Bayer will supply Fludara and Leukine.

Genzyme will take over the production of Leukine following FDA approval of a new, Seattle-area Leukine plant.

The transaction is expected to close in the second quarter, pending Federal Trade Commission review and international regulatory clearances.

Genzyme and Bayer will work closely to allow for an orderly transition of drug sales and distribution.

This process is expected to take place over a period of months following the close of the transaction, during which Bayer will provide transition services.

2 July 2009

Johnson & Johnson will acquire substantially all of the assets and rights of Elan related to its Alzheimer’s Immunotherapy Program (AIP Program), through a newly formed company.

Johnson & Johnson will invest $1 billion in Elan in exchange for newly issued American Depositary Receipts (ADRs) of Elan which will represent 18.4% of Elan’s outstanding ordinary shares.

Johnson & Johnson, will assume and continue Elan’s activities with Wyeth under the AIP Program and will initially commit up to $500 million to continue the development and launch activities of bapineuzumab as well as other compounds.

The agreement provides for additional funding obligations of the parties if needed.

Elan will receive a 49.9% equity interest in the newly formed Johnson & Johnson company that will acquire the AIP Program.

Elan will be entitled to a 49.9% share of the profits and certain royalty payments upon the commercialization of products under the collaboration with Wyeth.

Worldwide strategic alliance to discover, develop and commercialize new medicines based on Santaris Pharma's proprietary Locked Nucleic Acid (LNA) drug platform, which allows specific targeting and regulation of microRNAs (miRNAs) and messenger RNAs (mRNAs) as a means to affect gene expression mediated by the targeted RNAs.

Santaris Pharma will receive an upfront payment of $7 million in cash and Wyeth will make a $10 million equity investment in Santaris Pharma.

Santaris Pharma may receive further milestone payments of up to $83 million for each of 10 potential targets.

In addition, Santaris Pharma would receive royalties on the worldwide sales of all products arising from the alliance.

The term of the research portion of the collaboration is three years.

Wyeth has the right to extend the research portion up to two additional years.

Wyeth will select the RNA targets against which Santaris Pharma will use their proprietary LNA drug platform to generate unique drug candidates.

Wyeth will be responsible for the development and commercialization of products arising from the alliance.

Expanded agreement - January 2011

Santaris Pharma and Pfizer announced that the companies have expanded their collaboration directed to the development and commercialization of RNA-targeted medicines using Santaris Locked Nucleic Acid (LNA) Drug Platform.

Pfizer will make a payment of $14 million for access to Santaris LNA technology for the development of RNA-targeted drugs.

Santaris is eligible to receive milestone payments of up to $600 million as well as royalties on sales of products that may be developed for up to 10 new RNA targets selected by Pfizer.

The newly expanded alliance builds on the original collaboration formed in January 2009 between Santaris Pharma A/S and Wyeth, which was acquired by Pfizer Inc.

Under the terms of the original collaboration, Santaris Pharma A/S received an upfront payment of $7 million in cash and Wyeth made a $10 million equity investment in Santaris.

Santaris continues to be eligible to receive milestones and royalties under the original alliance.

Pfizer has advanced several programs under the original collaboration and reached a number of early milestones since the inception of the collaboration.

Collaboration and license agreement with Novartis for INCB18424 and INCB28060

Incyte will retain exclusive rights for the development and potential commercialization of INCB18424 in the US.

Novartis will have responsibility for the future development and commercialization of INCB18424 in all hematology–oncology indications outside of the US.

Novartis will also be responsible for the future worldwide development of INCB28060.

Novartis will make an upfront payment of $150 million to Incyte plus an immediate $60 million milestone payment

Novartis will receive ex-US commercialization rights for Incyte’s lead JAK inhibitor and global commercialization rights for the cMET inhibitor.

Each company will be responsible for costs in their respective territories for the JAK inhibitor, with costs of collaborative studies shared equally.

Incyte may also be eligible over time for additional payments of up to approximately $1.1 billion if future contingent development and commercialization milestones are achieved.

Incyte is also eligible to receive tiered, double-digit royalty payments on future ex-US INCB18424 sales.

Novartis will be responsible for all costs and activities for the cMET inhibitor after the Phase I clinical trial.

Incyte is eligible to receive royalties on future sales of INCB28060 and has retained an option to co-develop and co-promote INCB28060.

20 March 2012

AstraZeneca and Targacept announced top-line results from the remaining Phase 3 studies investigating efficacy, tolerability and safety of TC-5214 as an adjunct therapy to an antidepressant in patients with major depressive disorder who did not respond adequately to initial antidepressant treatment.

RENAISSANCE 4 and RENAISSANCE 5, both efficacy and tolerability studies, did not meet the primary endpoint of change on the Montgomery-Asberg Depression Rating Scale (MADRS) total score after eight weeks of adjunct treatment with TC-5214 as compared to placebo.

In both RENAISSANCE 4 and RENAISSANCE 5, as well as in the previously completed RENAISSANCE 2 and RENAISSANCE 3 studies, every dose group (TC-5214 and placebo) showed at least a 40 percent improvement in MADRS total score after eight weeks of adjunct treatment.

TC-5214 was overall well tolerated in RENAISSANCE 4 and RENAISSANCE 5 with an adverse event profile generally consistent with prior clinical trials.

In RENAISSANCE 7, a long-term study designed primarily to evaluate the safety of TC-5214, together with an antidepressant treatment, for one year, TC-5214 was overall well tolerated, with an adverse event profile generally consistent with prior clinical trials.

These studies conclude the RENAISSANCE Program for TC-5214.

Based on the totality of the results, AstraZeneca and Targacept will not pursue a regulatory filing for TC-5214 as an adjunct treatment for patients with MDD.

4 December 2009

Collaboration and license agreement for the global development and commercialization of TC-5214, Targacept’s late-stage investigational product for major depressive disorder (MDD).

TC-5214, which recently completed a phase IIb clinical trial, is a nicotinic channel blocker that is thought to treat depression by modulating the activity of various neuronal nicotinic receptor (NNR) subtypes.

AstraZeneca will make an upfront payment to Targacept of $200 million upon effectiveness and up to an additional $540 million if specified development, regulatory and first commercial sale milestones are achieved.

Targacept will also be eligible to receive up to $500 million if specified sales related milestones are achieved as well as significant stepped double-digit royalties on net sales worldwide.

Targacept has retained an option for a co-promotion of TC-5214 to a limited target physician audience in the US.

AstraZeneca and Targacept will jointly design a global phase III clinical program anticipated to begin in mid 2010 with the goal of filing a new drug application (NDA) with the US Food and Drug Administration (FDA) in 2012.

TC-5214 is being developed as an adjunct to antidepressant therapy in adults with MDD who do not respond adequately to first-line antidepressant treatment. The companies will also initiate a phase II study exploring TC-5214 as a monotherapy for MDD.

AstraZeneca will be responsible for 80% of the cost of the initial global development program, with Targacept responsible for the remaining 20%. AstraZeneca will be responsible for and will fund the costs of global commercialization of TC-5214, and will assume Targacept's manufacturing and supply agreements with third parties in relation to TC-5214.

The agreement also provides for a specified period for the parties to negotiate a potential multi-year research program that would be conducted by Targacept to identify and develop additional NNR Therapeutics for MDD and possibly other indications.

29 May 2009

Global license agreement for XL147 and XL765 and a broad collaboration for the discovery of inhibitors of phosphoinositide-3 kinase (PI3K) for the treatment of cancer.

Sanofi-aventis will have a worldwide exclusive license to XL147 and XL765, which are currently in phase 1 and phase 1b/2 clinical trials.

Exelixis will participate in conducting ongoing and potential future clinical trials and manufacturing activities.

Under the discovery collaboration, Exelixis and sanofi-aventis will combine efforts in establishing several pre-clinical PI3K programs and jointly share responsibility for research and preclinical activities related to isoform-selective inhibitors of PI3K.

Sanofi-aventis will pay Exelixis aggregate upfront cash payments of $140 million under the license and collaboration.

Exelixis will also receive guaranteed research funding of $21 million over a three year research term under the collaboration.

For the license and the collaboration, Exelixis will be eligible to receive development, regulatory and commercial milestones of over $1 billion in the aggregate, as well as royalties on sales of any products commercialized under the license or collaboration.

13 January 2009

Bristol-Myers Squibb agreed to pay ZymoGenetics an upfront cash payment of $85 million for the development and commercialization rights to PEG-Interferon lambda, and to pay an additional license fee of $20 million in 2009.

ZymoGenetics could receive additional payments of up to $430 million based on pre-defined development and regulatory milestones for PEG-Interferon lambda in Hepatitis C, up to $287 million in development and regulatory milestones for other potential indications, and up to $285 million based on pre-defined sales-based milestones.

The companies have agreed to co-develop PEG-Interferon lambda in the United States and Europe and will share development costs.

ZymoGenetics will have the option to co-promote in the United States and to share profits on product sales with Bristol-Myers Squibb.

ZymoGenetics may opt out of the co-development, co-promotion and profit sharing arrangement in the United States, in which case ZymoGenetics will receive double-digit royalties on PEG-Interferon lambda sales worldwide.

Outside the United States, Bristol-Myers Squibb will be responsible for commercialization and ZymoGenetics will receive double-digit royalties on product sales.

Definitive agreement with MDS Inc. to acquire the Analytical Technologies division of MDS, which includes a 50% ownership position in Applied Biosystems/MDS Sciex joint venture, a mass spectrometry business, and a 100% ownership position in the former Molecular Devices Corporation, a bioresearch and analytical instrumentation company.

In a separate, but related transaction, Danaher also announced that it has signed a definitive agreement with Life Technologies Corporation to acquire the remaining 50% ownership position in AB SCIEX.

After completion of both transactions, Danaher will own outright AB SCIEX and Molecular Devices.

The aggregate purchase price for the combined transactions is $1.1 billion, including debt assumed and net of cash acquired.

The acquired businesses will operate within Danaher's Medical Technologies segment, joining Danaher's Leica, Radiometer, Sybron, and KaVo businesses, and will expand the segment's annual revenues by more than $650 million.

The acquired businesses will increase Danaher's life sciences and diagnostics annual revenues to more than $2 billion.

Danaher's Medical Technologies brands are some of the most highly recognized in each of their respective product segments.

2 November 2009

Worldwide exclusive license, development and commercialization agreement to co-develop and commercialize pharmaceutical products for the treatment of obesity and related indications.

The agreement includes products to be developed from Amylin's pipeline, including pramlintide/metreleptin and davalintide, which are compounds currently in phase 2 development for treatment of obesity.

The agreement also includes additional compounds from both companies' obesity research programs.

Amylin will receive a one-time up-front payment of $75 million from Takeda and, over the term of the agreement is eligible to receive additional payments upon achieving certain development, commercialization and sales-based milestones that could exceed $1 billion.

The agreement also provides for future tiered, double-digit royalty payments to Amylin based on global product sales.

Amylin will be responsible for executing development activities for potential products through phase 2 with the aim of regulatory approval in the U.S.

Takeda will lead development activities beyond phase 2 in the U.S., and all development activities outside the U.S.

Amylin will be responsible for 20% of development costs associated with obtaining approval for products in the U.S. and Takeda will be responsible for 80% of such U.S. development costs.

Takeda will be responsible for 100% of development costs associated with obtaining approval for products outside the U.S.

Takeda will lead product commercialization, both in the U.S. and outside the U.S., and will be responsible for 100% of commercialization costs.

Amylin will have the option to co-commercialize the first two approved products in the U.S. and any follow-on products containing the identical active ingredients.

Global agreement for the development and commercialization of ALD518, a novel biologic that has completed Phase IIa development for the treatment of rheumatoid arthritis.

Alder will grant to Bristol-Myers Squibb worldwide exclusive rights to develop and commercialize ALD518 for all potential indications except cancer, for which Alder will retain rights and grant Bristol-Myers Squibb an option to co-develop and commercialize outside the United States.

An upfront cash payment of $85 million, potential development-based and regulatory-based milestone payments of up to $764 million across a range of indications, potential sales-based milestones which, under certain circumstances, may exceed $200 million, and royalties on net sales are payable to Alder by Bristol-Myers Squibb.

Alder has an option to require Bristol-Myers Squibb to make an equity investment of up to $20 million in Alder during an initial public offering.

Roche will fund research to be conducted by Synta during an initial two-year research period.

Roche will receive worldwide rights to develop and commercialize certain products identified prior to the end of this research period.

Roche is responsible for development and commercialization, while Synta retains the right, in indications other than rheumatoid arthritis, to co-develop, by conducting preclinical development and early clinical trials, and to co-promote in the USA, both at Roche’s expense.

Synta will receive $25 million in upfront cash license fees and committed research support, of which $9 million will be provided in the form of research support over the initial research period.

Synta will also be eligible to receive additional payments.

$245 million for the first product and half of this amount for each of the second and third products, and for commercialization milestones, up to $170 million for each of three products.

Synta will receive tiered royalties on all product sales.

Collaboration to develop macrophage-targeted compounds using Chroma’s proprietary esterase-sensitive motif (ESM) technology, which adds amino acid esters to compounds with the aim of targetting the compounds to specific cells in the inflammatory disease process.

Chroma will undertake four discovery and development programmes to identify small molecule therapeutics, including its macrophage-targeted HDAC inhibitor programme for inflammatory disorders such as rheumatoid arthritis.

Chroma will receive a significant up-front cash payment and, in addition, GSK will invest in Chroma’s Series D equity financing.

Chroma is eligible to receive milestones, option fees and tiered royalties based on compounds arising from the collaboration.

Overall, Chroma has the potential to receive in excess of $1 billion in total milestone and option payments in the event that all four programmes are successful.

For each program, Chroma will have responsibility for research and development activities through completion of clinical proof of concept studies.

After the completion of such studies for each programme, or earlier if it so chooses, GSK may elect to obtain an exclusive, worldwide license to product candidates within the program.

At such time GSK will assume full responsibility for development and commercialisation.

Chroma will retain full rights to further develop and commercialise its product candidates in any programme GSK chooses not to license.

3 June 2009

The deal includes three of Concert’s research and development programs; namely, CTP-518, a protease inhibitor for the treatment of HIV expected to enter Phase I clinical trials in the second half of 2009, a preclinical compound for chronic renal disease, and a third research product in Concert’s pipeline.

Concert will also provide GSK with deuterium-modified versions of three GSK pipeline compounds for GSK to develop.

Concert will receive $35 million in upfront payments, including a $16.7 million equity investment by GSK.

Concert is eligible to receive milestones and tiered, double-digit royalties based on deuterium-containing products arising from the Concert pipeline programs.

In addition, Concert is eligible to receive milestones as well as royalties on the sales of deuterium-containing products arising from the GSK pipeline compounds.

Overall, Concert has the potential to receive in excess of $1 billion in total milestone and upfront payments from GSK spread across all programs.

For each Concert pipeline program, Concert will have responsibility for research and development activities through completion of pre-agreed clinical trials.

After the completion of such clinical trials for each program, or earlier if it chooses, GSK may elect to obtain an exclusive, worldwide license to product candidates within the program.

At such time, GSK will assume responsibility for development and commercialization. Concert will retain full rights to further develop and commercialize its product candidates in any program GSK chooses not to license.

Exclusive research collaboration and licensing agreement with Roche for the development of orally bioavailable small molecules utilizing PTC's technology called Gene Expression Modulation by Small-molecules (GEMS(TM)).

The collaboration focuses initially on four CNS disease targets to be jointly selected.

Roche will make an upfront cash payment of $12 million and fund PTC's research efforts.

Subject to achievement of several successive milestones, there is the potential for PTC to earn up to $239 million in research, development, regulatory and commercial milestone payments per target.

PTC would also receive up to double digit royalties for all products resulting from this collaboration.

Roche has the option to add four targets to the collaboration across therapeutic areas, for additional cash payments.

9 April 2009

Collaboration and license agreement for the development and commercialization of vernakalant..

The agreement provides Merck with exclusive global rights to the oral formulation of vernakalant (vernakalant [oral]) and provides Merck Sharp & Dohme (Switzerland) GmbH, with exclusive rights outside of the United States, Canada and Mexico to the intravenous (IV) formulation of vernakalant (vernakalant [IV]).

Merck will pay Cardiome an initial fee of US$60 million.

Cardiome is eligible to receive up to US$200 million in payments based on achievement of certain milestones associated with the development and approval of vernakalant products (including a total of US$35 million for initiation of a planned Phase III program for vernakalant [oral] and submission for regulatory approval in Europe of vernakalant [IV]), and up to US$100 million for milestones associated with approvals in other subsequent indications of both the intravenous and oral formulations.

Cardiome will receive tiered royalty payments on sales and has the potential to receive up to US$340 million in milestone payments based on achievement of significant sales thresholds.

Cardiome has retained an option to co-promote vernakalant (oral) with Merck through a hospital-based sales force in the United States.

Merck will be responsible for all future costs associated with the development, manufacturing and commercialization of these candidates.

Merck has granted Cardiome a secured, interest-bearing credit facility of up to US$100 million that Cardiome may access in tranches over several years commencing in 2010.

3 September 2009

Global agreement with Bayer for the development and commercialization of Algeta's first-in-class alpha-pharmaceutical, Alpharadin.

Alpharadin is currently being evaluated in a global phase III trial in men with hormone-refractory prostate cancer (HRPC) that has spread to the bone.

Algeta has an option for up to 50% co-promotion with Bayer in the United States under a profit-share arrangement.

Bayer will commercialize Alpharadin globally and pay tiered double-digit royalties on net sales in markets where there is no co-promotion.

The Alpharadin deal with Bayer totals up to $800 million (EUR560m) to Algeta.

This is made up of an upfront payment of $61 million (EUR42.5m) plus further cash payments based upon the achievement of certain development, production and commercialization milestones.

Algeta will be responsible for manufacturing and supply of the commercial product.

Bayer will also contribute a substantial majority of the costs of future development of Alpharadin as a treatment for bone metastases resulting from HRPC and from other cancer indications, and will fully fund any additional late-stage trials.

27 February 2009

Agreement to divest its diagnostic systems business to Beckman Coulter, Inc.

The divestment is scheduled for July 1, 2009, pending regulatory approval.

The total value of the transaction is 77.5 billion yen.

The specifics of the divestment process will conform to the local legal and regulatory jurisdictions in which each subsidiary operates.

Beckman will pay the purchase price by a combination of cash and Beckman stock.

2 August 2009

Beckman Coulter announced the completion of the acquisition of Olympus’ lab-based diagnostics business.

This acquisition, first announced in February, extends Beckman Coulter’s leadership position in Chemistry and Automation.

Beckman Coulter delivered approximately USD $780 million, which was funded as follows:

Approximately $495 million in net proceeds raised from the issuance of two $250 million senior note offerings of 6- and 10- year maturities with 6% and 7% coupons, respectively.

Approximately $240 million in a common stock offering comprised of approximately 4.7 million shares issued to the public at $53.00 per share, or $50.75 net proceeds per share. In connection with the offering, Beckman Coulter entered into forward sale agreements which were settled July 27, 2009, at which time the newly issued shares were added to Beckman Coulter’s total outstanding shares.

27 October 2009

Global agreement to develop and commercialize MDV3100, Medivation's investigational drug for the treatment of prostate cancer.

MDV3100 is currently being evaluated in the Phase 3 AFFIRM clinical trial in men with castration-resistant prostate cancer who were previously treated with docetaxel-based chemotherapy.

Medivation will receive an up-front cash payment of $110 million.

Medivation is also eligible to receive payments of up to $335 million upon the attainment of development and regulatory milestones plus up to an additional $320 million in commercial milestone payments.

The companies will jointly commercialize MDV3100 in the U.S.

The companies will share equally all U.S. development costs, commercialization costs, and profits.

Astellas will have responsibility for developing and commercializing MDV3100 outside the U.S. and will pay Medivation tiered double-digit royalties on ex-U.S. sales.

21 December 2009

Exclusive worldwide license and collaboration agreement for the development and commercialization of JAK1/JAK2 inhibitor, INCB28050, and certain follow on compounds, for inflammatory and autoimmune diseases.

Lilly will receive worldwide rights to develop and commercialize INCB28050 as an oral treatment for all inflammatory conditions.

Incyte will receive an initial payment of $90 million and up to $665 million in additional development, regulatory, and commercialization milestones, as well as tiered, double-digit royalty payments on future global sales with rates ranging up to twenty percent.

Incyte will retain the option to co-develop its JAK1/JAK2 inhibitors with Lilly on a compound-by-compound and indication-by-indication basis beginning at the initiation of Phase IIb development.

Incyte would be responsible for funding thirty percent of the associated future global development costs from the initiation of a Phase IIb trial.

Incyte would receive an incremental royalty rate increase across all tiers resulting in effective royalty rates ranging up to the high twenties on potential future global sales for compounds and/or indications that Incyte elects to co-develop.

Incyte consider exercising a co-development option would be in the second half of 2010.

Smith & Nephew and the vendors of Plus have reached an agreement to reduce the total original purchase price by CHF 159 million ($141 million) from CHF 1086 million ($889 million at then prevailing rates) paid in May 2007.

As part of the agreement the parties have resolved their disputes on the contractual purchase price adjustments.

In addition, Smith & Nephew is releasing the vendors from substantially all of their warranties, including those relating to taxation, under the original purchase agreement and has dropped all existing claims under the original warranties.

21 September 2009

Exclusive worldwide license agreement for the NKTR-118 and NKTR-119 programmes

Nektar will receive an upfront payment of $125 million for both NKTR-118 and NKTR-119.

For NKTR-118 Nektar is eligible to receive up to $235 million in aggregate payments upon the achievement of certain regulatory milestones, as well as additional tiered sales milestone payments of up to $375 million.

Nektar will also be eligible to receive significant double-digit royalty payments on net sales of NKTR-118 worldwide.

AstraZeneca will continue the development of the NKTR-119 programme, including determining the appropriate opioid combinations with NKTR-118.

For NKTR-119 Nektar would receive development milestone payments as well as tiered sales milestone payments.

Nektar will also receive significant double-digit royalty payments on NKTR-119 net sales worldwide.

Agreement with Boston Scientific resolving its Palmaz infringement suit relating to Bostons NIR stent, settling several other cardiology-related cases relating to patents in the Ding, Kastenhofer, Palmaz, and Fontirroche patent families, and exchanging paid-up licenses for certain intellectual properties.

In addition, Boston will pay Cordis Corporation $716.3 million on October 1.

Johnson & Johnson expects to record the majority of this payment as a special item during the fourth quarter.

Cash compensation of EUR 515 million upon closing of the transaction expected in late March 2009.

The commercial operations and product distribution rights to be acquired by GSK represent approximately 3-4% (three to four percent) of UCB's 2008 expected revenue of at least EUR 3.3 billion.

The agreement includes more than fifty UCB operations in the following geographic regions: Far-East, Middle-East, Latin America and Africa.

This agreement does not include among other countries: Brazil, Russia, India, China, South-Korea or Mexico which are considered by UCB as strategic emerging markets.

The agreement covers principally all currently marketed UCB products and staff in the regions mentioned above.

It does not include UCB's new core products such as Vimpat® (lacosamide), Neupro® (rotigotine), Cimzia® (certolizumab pegol), nor does it provide rights to any of UCB's research & development pipeline programmes.

Exclusive worldwide collaboration for the development and commercialization of RNA based therapeutics for Duchenne Muscular Dystrophy (DMD).

The alliance includes four RNA-based products intended to treat specific, but different, subpopulations of patients suffering from DMD.

GSK will obtain an exclusive worldwide license to develop and commercialize Prosensa’s lead compound, PRO051, intended to treat DMD by skipping exon 51 of the dystrophin gene.

GSK’s Neurosciences Medicines Development Centre will continue to progress the further development of PRO051 in collaboration with Prosensa.

Both parties have begun preparations for a Phase III study which is intended to start in early 2010.

GSK will fund all costs associated with the further clinical development of PRO051.

GSK has exclusive options to license three more RNA-based compounds targeting additional DMD exons.

One such option includes Prosensa’s second lead compound, PRO044, which targets the skipping of exon 44 and for which Prosensa expects to initiate a Phase I/II study before the end of 2009.

In this case, GSK’s option rights will be triggered by a successful completion of this study.

The financial terms include a GBP 16 million (USD 25 million) upfront payment.

Prosensa is eligible to receive up to GBP 412 million (USD 655 illion) in milestones payments if all four compounds are successfully developed and is also entitled to double-digit royalties on product sales.

Prosensa will retain commercial participatory rights, and has an option to expand its commercial rights, in certain European countries on products arising under the collaboration.

Expansion agreement - June 2010

Prosena has initiated of two further programmes under its existing alliance with GSK covering novel RNA-based treatments for Duchenne Muscular Dystrophy (DMD).

The initiation of these additional programs under the terms of the existingalliance agreement is a validation of both the potential of Prosensa’s “exon skipping” platform and the ongoing relationship.

Under the terms of the collaboration, GSK has an option to select two of these additional four compounds for later-stage development and commercialization.

Prosensa will retain certain limited European commercialization rights alongside GSK for the two compounds selected by GSK.

For the two compounds not selected by GSK, Prosensa will retain full commercialization rights.

Exclusive development, manufacturing and commercialisation agreement in the United States for Daxas(®) (roflumilast), a once-daily oral treatment for patients suffering from symptomatic Chronic Obstructive Pulmonary Disease (COPD).

Nycomed will retain marketing rights to Daxas in Europe and the rest of the world.

Forest Laboratories will make an upfront payment of US$100 million and additional milestone payments to Nycomed based on defined regulatory and commercialisation achievements.

Nycomed will also receive royalties on US net sales typical for a product, which is in registration.

Forest will assume responsibility for the US regulatory approval and commercialisation of Daxas in the United States and the companies will collaborate on future development programs.

Other details of the financial terms of the agreement were not disclosed.

Exclusive worldwide license agreement with Novartis.

The agreement is to develop and commercialize elinogrel, Portola's novel, proprietary intravenous (i.v.) and oral P2Y12 ADP receptor antagonist currently in Phase 2 clinical development.

Novartis will make an upfront cash payment of $75 million to Portola.

Portola is eligible to receive additional cash payments totaling up to $500 million upon achievement of certain development, regulatory and commercialization milestones.

Portola will also receive royalties on worldwide net sales of elinogrel and have the option to co-promote elinogrel in the United States limited to hospitals and specialty markets.

Novartis will fund all future Phase 3 clinical trials of elinogrel and share costs of ongoing and planned Phase 2 trials.

The agreement also provides Portola with an option to co-fund Phase 3 clinical trials and other development activities in return for additional royalties.

Agreement with Novartis whereby Novartis has been granted an exclusive option to acquire Proteon following the successful completion of a Phase 2 clinical study of PRT-201 with a potential secondary right to a global license under pre-agreed conditions.

Including the initial acquisition payment plus potential additional regulatory milestone payments, the deal with Novartis could exceed $550 million.

4 May 2011

S*BIO has regained North American and European rights to its novel JAK2 inhibitors, SB1518 and SB1578, from Onyx.

Following a successful and productive partnership with Onyx, S*BIO will now be in a position to drive the development of its lead JAK2 program independently.

7 January 2009

Onyx has obtained option rights to exclusively develop and commercialize SB1518 and SB1578for all potential indications in the United States, Canada, and Europe.

SBIO will retain responsibility for all development costs prior to option exercise, after which Onyx will assume development costs for the U.S., Canada, and Europe subject to SBIO's option to fund a portion of the development costs in return for enhanced royalties on any future product sales.

Upon option exercise for each compound, S*BIO will receive a one-time fee, milestones upon achievement of certain development and sales triggers and royalties on future product sales.

In December 2008, Onyx made a $25 million payment to S*BIO, including an up-front payment and an equity investment.

Expanded agreement - May 2010

SBIOand Onyx Pharma expanded their development collaboration and option and license commercialization agreement for SBIO's novel JAK2 inhibitors, SB1518 and SB1578.

Onyx will provide $20 million in funding to broaden and accelerate the existing development program for both compounds.

The program will be expanded to include new indications for hematologic malignancies and myeloproliferative disorders.

S*BIO will continue to perform the clinical development of SB1518 (ONX 0803) and preclinical through clinical development of SB1578 (ONX 0805).

Worldwide strategic collaboration focused on the discovery, development and commercialization of multiple product candidates based on powerful, targeted molecular immunotherapy for the treatment of cancer.

GlobeImmune will receive a $40 million upfront payment from Celgene, which includes an equity investment in GlobeImmune.

GlobeImmune is granting Celgene an exclusive option to all oncology programs, including GI-4000, a Tarmogen technology-based product currently in phase II pancreatic cancer studies as well as all of GlobeImmune's other oncology product candidates on a program by program basis.

GlobeImmune will conduct the early development of the product candidates through certain pre-defined endpoints.

Celgene will have the option to obtain an exclusive worldwide license to develop and commercialize these unique immunotherapy product candidates.

GlobeImmune is eligible to receive over $500 million in development and regulatory milestones, double-digit royalties and additional milestone payments based on net sales of the licensed product candidates.

Exclusive worldwide option and licensing agreement for a nicotine conjugate candidate vaccine (NicVAX(R)), an investigational vaccine for the treatment of nicotine addiction and the prevention of smoking relapse, as well as for the development of a second generation nicotine vaccine.

GSK will pay to Nabi an upfront non-refundable fee of $40 million at closing and will receive an option to exclusively in-license NicVAX on a worldwide basis and a license to develop follow-on next-generation nicotine vaccines using Nabi's intellectual property.

Together with the upfront payment, Nabi is eligible to receive over $500 million in option fees and regulatory, development and sales milestones for NicVAX and follow-on nicotine vaccines.

Nabi will also receive double-digit royalties on global sales of NicVAX should GSK exercise its option as well as royalties on global sales of next generation nicotine vaccines.

NicVAX has recently entered the first of two Phase III clinical trials. Nabi will be responsible at its cost for the Phase III development of this candidate vaccine.

Upon successful completion of the Phase III studies, if GSK exercises its option, GSK will take responsibility for further development and commercialisation of NicVAX.

In parallel with the Phase III studies, and independent of whether it exercises its option to in-license NicVAX, GSK will be developing a next-generation nicotine vaccine based on Nabi's intellectual property together with GSK's own technology.

Exclusive worldwide licensing agreement for the development and co-commercialization of MM-121, a first-in-class, fully human monoclonal antibody designed to block signaling of the ErbB3 receptor.

MM-121 is currently in Phase 1 clinical testing.

Sanofi-Aventis will make an upfront payment of $60 million and will be responsible for all development costs.

Merrimack is eligible for an additional $470 million in milestone payments as well as tiered double-digit royalties on sales of MM-121.

Merrimack will execute the development of MM-121 through Phase 2 proof of concept for each indication and sanofi-aventis will be responsible for development thereafter.

Merrimack retains the right to co-promote the therapy in the United States.

1 July 2009

Exclusive collaboration and license agreement to develop and commercialize Fampridine-SR, a multiple sclerosis (MS) therapy, in markets outside the United States.

Fampridine-SR is a novel, oral sustained-release compound being developed to

The parties have also entered into a related supply agreement.

The transaction represents a sublicensing of an existing license agreement between Acorda and Elan Pharma International Limited, a subsidiary of Elan Corporation plc.

Biogen Idec will commercialize Fampridine-SR and any aminopyridine products developed under the agreement in ex-U.S. markets worldwide and will also have responsibility for regulatory activities and future clinical development of Fampridine-SR in those markets.

Acorda will receive an upfront payment of $110 million and additional payments of up to $400 million based on the successful achievement of future regulatory and sales milestones.

Biogen Idec will make tiered, double-digit royalty payments to Acorda on ex-U.S. sales, and, in addition, the consideration that Biogen Idec pays for products will reflect all amounts due from Acorda to Elan for ex-US sales, including royalties owed.

The parties can also carry out future joint development activities under a cost-sharing arrangement.

Elan will continue to manufacture commercial supply of Fampridine-SR, based on its existing supply agreement with Acorda.

Under the existing agreements with Elan, Acorda will pay Elan seven percent of the upfront and milestone payments that Acorda receives from Biogen Idec.

6 May 2009

Agreement to divest full commercial rights to Wellbutrin XL® in the United States to Biovail International Laboratories SRL, a subsidiary of Biovail Corporation, for $510 million (euro 340 million).

GSK will transfer the US NDA and license the Wellbutrin XL trademark to Biovail for use in the US.

GSK will retain existing rights to Wellbutrin XL (excluding Canada) for countries outside the US.

25 March 2011

Novartis and Peptimmune recently terminated the option deal because it called for Peptimmune to fund further development of the drug, which it could no longer do.

15 January 2009

Exclusive option to obtain exclusive worldwide rights to develop and commercialize PI-2301, Peptimmune's multiple sclerosis drug candidate.

In a separate but related agreement, the MPM Bio IV NVS Strategic Fund L.P. made an equity investment in Peptimmune.

In the event that Novartis exercises the option to PI-2301, Novartis would assume the global clinical development, manufacturing, and marketing of PI-2301 and all associated costs.

Peptimmune would receive payments upon the option exercise and upon successful completion of certain development, regulatory, and commercial milestones.

These payments together could total more than $500 million.

In addition, Peptimmune shall be eligible to receive royalties on product sales.

Additional terms were not disclosed.

Novartis has been granted an exclusive option to acquire Elixir following the successful completion of a Phase 2a clinical study of Elixir’s lead oral ghrelin antagonist, currently in preclinical, IND-enabling studies.

Including the initial acquisition payment plus potential additional regulatory and sales milestone payments, the deal with Novartis could exceed $500 million.

The agreement also includes a right to an exclusive worldwide license under pre-agreed conditions.

Exclusive worldwide collaboration for the discovery, development and commercialization of Factor VIIa products to treat hemophilia and other bleeding conditions.

Total payments under the collaboration, including an upfront payment of $21 million, research funding and milestone payments, could exceed $500 million, exclusive of royalty payments.

Through the collaboration, Wyeth will support the discovery, research and preclinical development by Catalyst of Factor VIIa products, including CB 813, Catalyst's investigational candidate drug for the treatment and prophylaxis of acute bleeding in patients with hemophilia.

The term of the exclusive research portion of the collaboration is two years, and may be extended by Wyeth for up to three additional years.

During the research term of the agreement, Catalyst will receive support for up to twelve full-time employees.

Wyeth will be responsible for the development, manufacturing and worldwide commercialization of products resulting from the collaboration.

In addition, during the research term, Wyeth would have the right of first negotiation for any additional clotting factors discovered by Catalyst to treat hemophilia and other bleeding conditions.

Catalyst anticipates it would earn payments of up to $40 million or more over the next two years, including the upfront payment, committed research funding and preclinical and clinical milestone payments.

In addition, Catalyst will be eligible to receive escalating clinical development and commercialization milestones, plus tiered double-digit royalties on sales of products resulting from the collaboration.

Collaboration agreement with GlaxoSmithKline to discover, develop and commercialise novel compounds directed against multiple therapeutic targets of interest to GSK.

Astex will apply its world-leading fragment chemistry platform, Pyramid, to multiple targets identified by GSK, with the objective of identifying and developing new candidate drugs.

The targets have been selected from multiple therapeutic areas within GSK.

Astex and GSK will form joint programme teams to identify candidate compounds.

Astex will be primarily responsible for the initial fragment screening and lead discovery, and GSK will primarily be responsible for optimisation of the identified lead compounds.

GSK will be solely responsible for completing pre-clinical and clinical development of all products arising from the collaboration, and for their commercialisation globally.

The agreement provides for an upfront payment and equity investment in Astex of £20 million ($33 million), comprising £12.5 million in cash and £7.5 million in equity.

Astex is eligible to receive development and regulatory milestones and tiered royalties for each programme.

Total payments under the collaboration, excluding royalties, could reach over £300 million ($500 million), including non-clinical milestones totalling more than £37 million ($61 million), if all programmes under the alliance are successfully developed and commercialised.

Sanofi-aventis and Merrimack Pharmaceuticals enter into a WorldwideCollaboration and Licensing Agreement on MM-121.

Merrimack eligible to receive up to $530 million, comprised of $60 million upfront plus milestone payments, in addition to future royalties.

Merrimack will lead MM-121 development through proof of concept and retains the right to co-promote in the United States.

7 April 2008

Novartis to first acquire 25% stake from Nestlé for USD 143.18 per share for approximately USD 11 billion, closing expected in second half of 2008

In optional second step, Novartis has exclusive right to acquire Nestlé's remaining 52% stake for a fixed price of USD 181 per share, totaling about USD 28 billion; Nestlé has right to require Novartis to buy this stake.

Novartis and Nestlé have reached an agreement for a two-step transaction providing a path for the transfer and smooth transition to Novartis of Nestlé's ownership of 77% of Alcon's outstanding shares, which totaled 298.1 million as of April 4, 2008. These transactions will require regulatory approvals.

In the first step, Novartis will acquire a 25% stake in Alcon for about USD 11 billion through the purchase of approximately 74 million shares held by Nestlé. This reflects a per-share price of USD 143.18, which is Alcon's volume-weighted average share price between January 7, 2008, and April 4, 2008. Alcon's closing share price was USD 148.44 on April 4, the last trading day before the signing of this agreement.

In the second step, Novartis has the right to acquire Nestlé's remaining 52% majority stake in Alcon between January 1, 2010, and July 31, 2011, for a fixed price of USD 181 per share, or approximately USD 28 billion. During this period, Nestlé has the right to require Novartis to buy its remaining stake at a 20.5% premium to Alcon's share price at the time of exercise, but not exceeding USD 181 per share. Based on Alcon's closing share price on April 4, 2008, the combined premium would be a maximum of 13% to complete the two steps. Novartis has no obligation to purchase the remaining 23% of shares held by Alcon minority shareholders at any time.

Novartis intends to finance the purchase of the 25% Alcon stake in the first step from internal cash reserves and external short-term financing, with borrowing needs currently estimated at USD 5.5 billion. Financing for the second step would be supported by the Group's ongoing cash generation and further external borrowing.

Exclusive worldwide collaboration (excluding Japan) for Actelion's almorexant, an orexin receptor antagonist in phase III development with first-in-class potential as a treatment for primary insomnia.

GSK will receive exclusive worldwide rights to co-develop and co-commercialise almorexant.

Actelion will continue to lead the ongoing development programme and potential registration for almorexant in the first indication, primary insomnia, with GSK contributing 40 per cent of the costs.

Almorexant will also be studied in other orexin-related disorders and all costs related to these programmes will be shared equally.

Actelion will receive an upfront payment of CHF 150 million (approximately £66 million) and will be eligible for additional potential milestone payments of up to CHF 415 million in regards to the successful development and approval of almorexant in primary insomnia.

In addition, Actelion will be eligible to receive additional milestone payments, pending successful development of two other major indications for almorexant yet to be evaluated through clinical investigation.

If all three indications were successfully registered, approved and commercialised, and exceptional sales targets met for all these indications, Actelion would be eligible to receive additional potential milestone payments of up to CHF 2.735 billion.

Also, costs and profits resulting from this collaboration will be shared equally between the two companies.

7 January 2008

Strategic alliance in which Genzyme will develop and commercialize mipomersen, Isis’ lipid-lowering treatment for high risk cardiovascular patients that utilizes novel antisense technology.

As part of the strategic relationship, Genzyme will also have preferred access to future Isis drugs for CNS and certain rare diseases.

Genzyme will pay Isis $150 million to purchase five million shares of Isis common stock for $30 per share upon Hart-Scott-Rodino clearance.

Upon completion of final contracts, Genzyme will pay Isis a $175 million up-front mipomersen license fee.

In addition to this initial $325 million, Isis has the potential to receive significant milestone payments for mipomersen, which is currently in phase 3 trials.

Once the product is launched, the two companies will share profits.

Isis will transition development responsibility for mipomersen to Genzyme over the next two years.

In addition to the up-front payment, Isis also has the opportunity to receive from Genzyme up to $825 million in development and regulatory milestone payments plus up to $750 million in commercial milestone payments.

Genzyme and Isis will share mipomersen profits 50/50 when annual worldwide revenues reach $2 billion or more.

The profit share begins with a 70/30 Genzyme/Isis split and reaches 50/50 on a sliding scale as annual revenues ramp up to $2 billion.

Worldwide strategic collaboration for the joint development and commercialization of ACE-011, a first-in-class, novel bone-forming compound.

The collaboration combines both companies’ resources and commitment to developing products for the treatment of cancer and cancer-related bone loss.

In pre-clinical and early clinical studies, this innovative compound has reported success in key biomarkers of bone formation.

The companies also signed an option agreement for certain discovery stage programs.

Celgene and Acceleron will jointly develop, manufacture and commercialize Acceleron’s products for bone loss.

Celgene will make an upfront payment to Acceleron of $50 million, which includes a $5 million equity investment in Acceleron.

In addition, in the event of an initial public offering of Acceleron, Celgene will purchase a minimum of $7 million of Acceleron common stock.

Acceleron will retain responsibility for initial activities, including research and development, through the end of Phase 2a clinical trials, as well as manufacturing the clinical supplies for these studies.

In turn, Celgene will conduct the Phase 2b and Phase 3 clinical studies and will oversee the manufacture of Phase 3 and commercial supplies.

Acceleron will pay a share of the development expenses and is eligible to receive development, regulatory and commercial milestones of up to $510 million for the ACE-011 program and up to an additional $437 million for each of the three discovery stage programs.

The companies will co-promote the products in North America.

Acceleron will receive tiered royalties on worldwide net sales.

Worldwide strategic alliance for the discovery, development and commercialization of novel medicines for bacterial diseases.

The collaboration provides GlaxoSmithKline access to Mpex's novel efflux pump inhibitors (EPI) and related proprietary technology for use in combination with a variety of antibiotics.

The collaboration will focus on the discovery and development of novel drug regimens comprising Mpex's EPIs combined with GSK's novel development stage compounds as well as existing commercial antibiotics to improve potency and broaden the spectrum of antibacterial activity.

Mpex will grant GlaxoSmithKline rights to product candidates developed under the collaboration that are directed to three different target product profiles and with the potential to deliver up to seven treatment options.

Mpex will be responsible for the discovery of EPI drug candidates and the development of combination product candidates through clinical proof of concept, at which point GlaxoSmithKline will have an option to exclusively license each product candidate for further development and commercialization on a worldwide basis.

Mpex will retain the right to further develop and commercialize product candidates for which GlaxoSmithKline does not exercise its option.

Mpex will receive an $8.5 million upfront payment and a $6.5 million equity financing commitment from GlaxoSmithKline.

Contingent on achieving certain milestones, Mpex is eligible to receive development, regulatory and commercial milestones ranging up to $200 to $250 million for each product candidate.

If GlaxoSmithKline exercises its option, Mpex will receive tiered royalties, which are dependent on sales achieved, for EPIs used in combination with commercially available antibiotics and with proprietary GSK antibiotics.

GlaxoSmithKline will participate in the alliance through its Infectious Diseases Centre of Excellence for Drug Discovery (ID CEDD).

Covance will acquire Lilly's 450-acre early drug development campus in Greenfield, Indiana for $50 million.

Covance will provide Lilly with a broad-range of drug development services over the next ten years for a contract value of $1.6 billion.

Covance will assume ownership of the site and operations on or about October 1, 2008.

Lilly will transfer responsibility to Covance for its non-GLP toxicology, in vivo pharmacology, quality control laboratory, and imaging services.

The contract includes a committed level of clinical pharmacology, central laboratory, GLP toxicology studies, and clinical Phase II-IV services.

Worldwide strategic alliance to discover, develop and commercialise aptamer therapeutics to treat inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease.

Aptamers are synthesized oligonucleotides, or short nucleic acid sequences, that bind to proteins with high affinity and specificity.

The alliance leverages Archemix’s unique expertise and intellectual property position in the discovery and development of aptamer therapeutics and provides GSK with an option to license product candidates directed at seven different aptamer targets with relevance in inflammatory disease.

Archemix will receive $27.5 million in upfront payments from GSK, including a $6.5 million equity investment by GSK in the company.

Archemix could also be eligible to receive up to $200 million in development, regulatory and sales milestone payments for each of the seven aptamer therapeutics which may be discovered and developed as part of the alliance.

Archemix would also receive tiered royalties up to lower double digits on worldwide sales of products that may result from the alliance.

Archemix will be responsible for the discovery and development of the aptamer therapeutics through completion of clinical proof of mechanism, unless GSK chooses to exercise its option earlier.

After exercise of the option, GSK will have an exclusive license to drug product candidates developed under each programme by Archemix for the relevant aptamer target for further development and commercialisation on a worldwide basis.

Archemix will have the right to further develop and commercialise any aptamer therapeutics which GSK chooses not to develop or commercialise.

9 February 2012

Osiris Therapeutics provided an update on the status of the development and commercialization agreement with Genzyme, a Sanofi company.

On Wednesday, February 8, 2012, Sanofi issued a press release, which included an update on their R&D pipeline, stating that it has "discontinued" its project with Prochymal for graft versus host disease.

The statement issued by Sanofi was made without consultation with or knowledge of Osiris.

Osiris has not received any notification from Sanofi regarding the discontinuation of the agreement in place between the two companies.

Through its legal counsel, Osiris has advised Sanofi that Osiris is treating these public statements as Sanofi's election to terminate the agreement.

The agreement provides that in this instance all rights to Prochymal revert back to Osiris without compensation to Sanofi, and Osiris is free to commercialize or enter into commercialization agreements for Prochymal with other parties without restriction.

4 November 2008

Strategic alliance for the development and commercialization of Prochymal and Chondrogen, two novel, late-stage adult stem cell treatments that hold significant potential to treat a wide range of diseases.

These stem-cell products are designed to provide therapeutic benefit by controlling inflammation, promoting tissue regeneration, and preventing scar formation.

Osiris will commercialize Prochymal and Chondrogen in the United States and Canada, and Genzyme will commercialize the treatments in all other countries.

Genzyme will make an up-front payment of $130 million to Osiris, plus potential significant milestone and royalty payments.

Osiris is responsible for the clinical development costs for all ongoing trials, as well as future trials for additional indications through completion of phase 2 development.

Osiris and Genzyme will share the cost of future Phase 3 and 4 clinical trials, with a 60 percent Osiris / 40 percent Genzyme split.

Genzyme will make a $130 million up-front payment to Osiris, with $75 million paid initially and $55 million to be paid on July 1, 2009.

In addition, Osiris also has the potential to receive a total of up to $1.25 billion in milestone payments from Genzyme as follows:

Osiris is eligible to receive up to $500 million in development and regulatory milestone payments for Prochymal related to GvHD, Crohn’s disease, and other potential additional indications that the companies develop together.

Based on sales in Genzyme territories, Osiris is eligible to receive up to $250 million in sales milestones for Prochymal as follows: $100 million payable when annual sales reach $500 million and $150 million payable when annual sales reach $1 billion.

Based on the results of the planned phase 2/3 trial of Chondrogen, Genzyme may elect to opt-out of further Chondrogen development, at which point all rights to Chondrogen will revert to Osiris with no further obligation by either company.

If Genzyme elects to continue with Chondrogen development, Osiris would be eligible to receive up to $100 million in development and regulatory milestones based on the achievement of certain clinical trial results and regulatory approvals. Based on sales in Genzyme territories, Osiris would be eligible to receive up to $400 million in sales milestones for Chondrogen.

Osiris is also eligible to receive significant escalating royalties on sales of Prochymal and Chondrogen within Genzyme territories.

Cellzome and GlaxoSmithKline have signed a worldwide strategic alliance to discover, develop and market novel kinase-targeted therapeutics to treat inflammatory diseases.

GSK has exclusive options to license drug candidates from Cellzome's kinase programs directed against four identified targets, and three additional targets to be jointly identified by both parties.

Cellzome is eligible to receive success-based milestones from GSK as product candidates are advanced.

Upon Cellzome's achievement of clinical proof of concept for a product candidate for a particular kinase target, GSK would have an exclusive option to license all product candidates from that program.

GSK would then assume full responsibility for further clinical development and commercialization on a worldwide basis.

Cellzome retains the right to continue the development and commercialization of drug candidates if GSK chooses not to exercise its option to that program.

Cellzome will receive upfront payments of GBP14.4 million comprised of both cash and equity.

Cellzome is eligible for up to GBP118 million per program in potential development, regulatory and commercial milestones and up to double digit royalties on net sales of products resulting from the alliance.

10 December 2008Cellzome Inc.announced today that it has successfully achieved the first milestone in the strategic alliance withGlaxoSmithKline (GSK) established earlier this year triggering payment of an undisclosed amount.

27 March 2009

Cellzome Inc has successfully achieved two further milestones for programs in its strategic alliance with GlaxoSmithKline.

The achievement of these second and third milestones triggers an individual payment for each milestone from GlaxoSmithKline.

The amounts of these payments are undisclosed.

Bristol-Myers Squibb Company and PDL BioPharma have an agreement for the global development and commercialization of elotuzumab currently in Phase I development for multiple myeloma.

Bristol-Myers Squibb would pay PDL BioPharma an upfront cash payment of $30 million for the development and marketing rights to elotuzumab and for an option to expand the collaboration to include PDL241, another anti-CS1 antibody, upon completion of pre-agreed preclinical studies.

PDL BioPharma could receive additional payments of up to $480 million based on pre-defined development and regulatory milestones and up to $200 million based on pre-defined sales-based milestones for elotuzumab in multiple myeloma and other potential oncology indications.

The companies will share development costs, with Bristol-Myers Squibb providing 80 percent of the funding and PDL BioPharma providing 20 percent.

Bristol-Myers Squibb will lead global development activities, and PDL BioPharma will complete the ongoing Phase I program and provide support for Phase II studies.

The companies would share profits on sales of elozutumab in the U.S. PDL BioPharma would receive royalties on net sales of elotuzumab outside the U.S.

If Bristol-Myers Squibb exercises its option to expand the collaboration to include PDL241, PDL BioPharma would receive an additional cash payment of $15 million and could receive additional payments of up to $230 million based on pre-defined development and regulatory milestones and up to $200 million based on pre-defined sales-based milestones.

The same division of development costs and profit sharing that apply to elotuzumab would apply to PDL241.

4 February 2008

Agreement under which Takeda will develop and commercialize for the Japanese market up to 13 molecules from Amgen's pipeline, one of which is included as an option.

This collaboration validates the significant value of Amgen's clinical stage pipeline and further ensures Japanese patients will have access to Amgen's innovative potential medicines for serious illnesses.

The collaboration includes early to mid-stage clinical-stage candidates across a range of therapeutic areas, including oncology, inflammation, and pain.

The financial terms include an upfront cash payment to Amgen of $200 million.

Takeda will also pay to Amgen up to $340 million in expected worldwide development costs for these molecules over the next several years, $362 million in success-based milestone payments, and double digit royalties on sales in Japan.

Takeda plans to acquire all the shares of Amgen's Japanese subsidiary, Amgen KK.

19 December 2008

Exclusive worldwide agreement to develop and commercialize Unit Dose Budesonide (UDB), MAP Pharmaceuticals' proprietary nebulized formulation of budesonide.

AstraZeneca will pay MAP Pharmaceuticals an upfront cash payment of $40 million and an additional $35 million upon the successful achievement of primary endpoint and safety results in the currently ongoing Phase III clinical study.

In addition, upon the occurrence of certain events and conditions, MAP Pharmaceuticals is eligible to receive up to $240 million in other potential development and regulatory milestones.

The agreement also provides for additional progressively demanding sales performance-related milestone payments of up to $585 million in the event the product is a considerable commercial success.

AstraZeneca also will support and fund the establishment of a MAP Pharmaceuticals sales force to co-promote UDB in the United States for a certain period of time after product launch.

MAP Pharmaceuticals is also eligible to receive significant double-digit royalty payments on net sales of UDB worldwide.

MAP Pharmaceuticals and AstraZeneca will develop UDB in the United States and AstraZeneca has rights to develop and commercialize UDB outside of the United States.

Under the agreement, AstraZeneca will be responsible for future UDB development costs and AstraZeneca will reimburse MAP Pharmaceuticals for the costs of future UDB development activities with respect to United States registration incurred by MAP Pharmaceuticals.

8 July 2011

Exelixis received written notification from Bristol-Myers Squibb Company of its decision to terminate the Amended and Restated Collaboration Agreement dated as of April 15, 2011 by and between the Company and Bristol-Myers Squibb, which amended and restated the Collaboration Agreement dated as of December 11, 2008 between Exelixis and Bristol-Myers Squibb on a worldwide basis as to XL281.

The termination is being made pursuant to the terms of the Agreement and will be effective as of the end of the day on October 8, 2011.

Bristol-Myers Squibb informed the Company that the termination was based upon Bristol-Myers Squibb’s review of XL281 in the context of Bristol-Myers Squibb’s overall research and development priorities and pipeline products.

Upon the effectiveness of the termination, Bristol-Myers Squibb’s license relating to XL281 will terminate and rights to XL281 will revert to the Company, and the Company will be entitled to receive, subject to certain terms and conditions, licenses from Bristol-Myers Squibb to research, develop and commercialize XL281.

The Company plans to wind down ongoing activities related to XL281 following the termination and does not currently expect to further research, develop or commercialize XL281 following the wind-down.

12 December 2008

Bristol-Myers Squibb and Exelixis announced a global collaboration covering two novel molecules, XL184 XL281.

BMS agreed to pay Exelixis an upfront cash payment of $195 million for the development and commercialization rights to both programs and to make additional license payments of $45 million in 2009.

The companies have agreed to co-develop XL184.

Exelixis will have the option to co-promote XL184 in the United States.

The companies will share worldwide development costs and commercial profits on XL184 in the United States.

Exelixis will be eligible to receive sales performance milestones of up to $150 million and double-digit royalties on sales outside the United States.

The clinical development of XL184 will be directed by a joint committee.

It is anticipated that Exelixis will conduct a significant portion of clinical development activities through 2010.

Exelixis may opt out of the co-development of XL184, in which case Exelixis would instead be eligible to receive development and regulatory milestones of up to $295 million, double-digit royalties on XL184 product sales worldwide, and sales performance milestones.

Bristol-Myers Squibb will receive an exclusive worldwide license to develop and commercialize XL281 and will be responsible for funding all future development.

Exelixis is eligible for development and regulatory milestones of up to $315 million, sales performance milestones of up to $150 million development and regulatory milestones

Terminaton agreement - June 2010

Exelixis has regained full rights to develop and commercialize XL184.

Exelixis and BMS were not able to align on the scope, breadth and pace of the ongoing clinical development of XL184.

As a result, BMS returned XL184 to Exelixis, thereby giving Exelixis the opportunity to advance the program as originally envisioned.

BMS will make a payment to Exelixis of $17 million in connection with the return of XL184.

28 August 2008

Valeant will grant GSK worldwide development and commercialization rights to retigabine, VRX698 and the other back-up compounds from the potassium channel opener discovery program in exchange for an upfront payment of $125 million to Valeant.

GSK will pay Valeant up to $545 million based on the achievement of certain regulatory, development and commercialization milestones and the development of additional indications for retigabine.

Valeant will co-commercialize with GSK and will share up to 50 percent of net profits within the U.S., Canada, Australia, New Zealand and Puerto Rico, and will receive up to a 20 percent royalty on net sales of retigabine outside those regions.

The two companies will jointly fund all global research and development expenses for retigabine, and GSK will completely fund the development of VRX698 and the other back-up compounds from the potassium channel opener discovery program.

Valeant could receive up to an additional $150 million based on the achievement of certain regulatory, development and commercial milestones for VRX698 and the back-up compounds and double-digit royalties on worldwide sales.

21 October 2011

Expansion of its worldwide strategic alliance with GlaxoSmithKline (GSK) focused on toll-like receptor (TLR) inhibitors.

The addition of a new target, TLR8, entitles Dynavax to receive a $3 million milestone payment from GSK.

Subject to reaching sales and development milestones, Dynavax has the potential to receive approximately $200 million in milestone payments over the term of the alliance.

Based on preclinical data, Dynavax and GSK will work to develop a TLR8 inhibitor for the treatment of multiple autoimmune and inflammatory diseases.

17 December 2008

Worldwide strategic alliance to discover, develop and commercialise novel inhibitors of endosomal Toll-like Receptors (TLRs) for the treatment of immuno-inflammatory diseases.

TLRs are key receptors of the innate immune system that can induce strong inflammatory responses.

Dynavax will receive an initial payment of $10 million for which GSK will receive an exclusive option over four programmes targeting autoimmune and inflammatory diseases such as lupus, psoriasis, and rheumatoid arthritis.

Dynavax is to conduct research and early clinical development in up to four programmes and is eligible to receive future potential development and commercialisation milestones totaling approximately $200 million per programme.

GSK can exercise its exclusive option to license each programme upon achievement of proof-of-concept or earlier upon certain circumstances.

After exercising its option, GSK will carry out further development and commercialisation of these products.

Dynavax will receive tiered, up to double-digit royalties on sales and has retained an option to co-develop and co-promote one specified product.

23 October 2008

Amgen to provide technology services in a deal worth as much as $800 million over eight years.

Estimated cost of $500 million over five years.

Includes a provision that allows Amgen to expand it for another three years, which would bring the total value to $800 million.

18 June 2006

BioInvent and ThromboGenics have a license agreement with Roche to jointly develop the anti-cancer agent TB-403.

Roche will pay BioInvent and ThromboGenics an upfront payment of €50 million.

BioInvent and ThromboGenics will receive a series of development and commercial milestones payemts for multiple indications, as well as double digit royalties on potential product sales, including any backup antibodies based on inhibition of PlGF.

ThromboGenics, which discovered TB-403, will receive 60% and BioInvent 40% of the revenue from the deal.

Roche will have a worldwide, exclusive license to develop and commercialize TB-403.

BioInvent and ThromboGenics will retain co-promotion rights for the product in the Nordic, Baltic and Benelux regions.

BioInvent and ThromboGenics are responsible for any remaining costs associated with the recently completed Phase Ia trial in healthy volunteers.

Roche will assume responsibility for all future development costs for this novel therapy, including the costs of the pending Phase Ib trial in patients to be run by BioInvent and ThromboGenics.

Roche will also provide funding to BioInvent and ThromboGenics for research on non-cancer indications and supply of clinical material until transfer of manufacturing.

26 January 2010

ThromboGenics and BioInvent have received a technology transfer success fee of EUR5 million from Roche under the terms of their strategic alliance for the novel anti-cancer antibody, TB-403.

The payment has been triggered by the successful transfer and implementation of technology and process development to Roche in relation to the ongoing clinical development of TB-403.

17 May 2010

BioInvent and ThromboGenics have announced that their partner Roche will begin an imaging study with the novel anti-cancer antibody TB-403 (RG7334) in patients with metastatic, treatment-refractory, colorectal and ovarian cancer.

BioInvent and co-development partner ThromboGenics will receive a milestone payment of €10 million from Roche under the terms of the strategic alliance agreement signed in June 2008.

ThromboGenics, which discovered TB-403, receives 60% and BioInvent 40% of all revenue from the alliance with Roche for this anti-cancer antibody.

Exclusive worldwide collaboration agreement to develop and commercialize products from CoMentis’ beta-secretase inhibitor program, including CoMentis’ lead candidate compound CTS-21166, an orally bioavailable, small-molecule beta-secretase inhibitor which is being developed as a disease-modifying treatment for Alzheimer’s disease.

The agreement also includes a research collaboration to develop additional beta-secretase inhibitors.

CoMentis will receive an upfront payment of $80 million and an equity investment of $20 million.

CoMentis has the opportunity to receive up to $660 million in development milestones and may also receive performance-based commercialization milestones.

CoMentis has the right to receive development milestones for next-generation beta-secretase inhibitors discovered under the terms of the research collaboration.

Astellas will fund 100% of the pre-Phase III global development costs and CoMentis will share the Phase III development costs.

Astellas has exclusive worldwide commercialization rights while CoMentis retains the right to co-promote in the U.S., where profit will be shared.

CoMentis will receive royalties on sales outside the U.S.

17 January 2012

Medivation and Pfizer will discontinue development of dimebon for all indications and will terminate the ongoing open label extension study in Alzheimer's disease.

The companies also announce that they will terminate their collaboration to co-develop and market dimebon pursuant to the terms of their collaboration agreement.

Agreement to develop and commercialize Dimebon, Medivation's investigational drug for treatment of Alzheimer's disease and Huntington's disease.

Dimebon currently is being evaluated in an international, confirmatory Phase III trial in patients with mild-to-moderate Alzheimer's disease (www.connectionstudy.com).

Medivation will receive an up-front cash payment of $225 million.

Medivation also is eligible to receive payments of up to $500 million upon the attainment of development and regulatory milestones plus additional undisclosed commercial milestone payments.

Medivation and Pfizer will collaborate on the Phase III program in Alzheimer's disease, Huntington's disease development and regulatory filings in the United States.

The companies will share all U.S. development and commercialization expenses along with U.S. profits/losses on a 60 percent/40 percent basis, with Pfizer assuming the larger share of both expenses and profit/losses.

In addition, Medivation will co-promote Dimebon to specialty physicians in the U.S.

Pfizer will have responsibility for development, regulatory and commercialization outside the U.S. and will pay Medivation tiered royalties on commercial sales outside of the U.S.

27 July 2011

Addex will regain from Merck & Co., Inc. its intellectual property surrounding ADX63365 and other mGluR5-targeted PAM candidates and backup candidates, a novel approach for treating schizophrenia.

The decision ends a 2008 license agreement under which Merck had received exclusive rights to mGluR5-targeted PAM.

3 January 2008

Exclusive worldwide license agreement with Merck & Co to develop ADX63365, an orally available drug candidate for the potential treatment of schizophrenia and other undisclosed indications.

Allosteric modulators are an emerging new class of therapeutic agents.

ADX63365, currently in preclinical development, is a positive allosteric modulator (PAM) that targets the metabotropic glutamate receptor 5 (mGluR5), which is believed to be important as a target for the treatment of schizophrenia and other conditions.

The deal also includes mGluR5 PAM backup compounds discovered by Addex.

Addex will receive $22 million upfront and is eligible for up to $455 million in research, development, regulatory and sales milestones for the first product developed for two indications and up to $225 million in additional development, regulatory and sales milestones for a second product developed in two indications.

Addex is eligible to receive royalties on sales of any products resulting from this collaboration.

In addition, Addex has an option to co-promote in certain European Union countries and will participate in the joint oversight committee for further development that will be led by Merck.

Aspen will own the four drugs in all major markets outside of the United States, except for rights to Zyloric in Japan.

Extended agreement - May 2009

GSK and Aspen will collaborate on the commercialisation of their current and future product portfolios in Sub-Saharan Africa (excluding South Africa).

The vast majority of combined current sales in this region (approximately 65 million pounds Sterling in 2008) are attributable to GSK.

Going forward, the collaboration will build a broader and more diverse portfolio for these countries, with Aspen's extensive pipeline of new products expected to benefit from greater leverage through GSK's existing commercial infrastructure.

GSK will divest eight specialist medicines to Aspen and a manufacturing facility located in Bad Oldesloe, Germany.

The products to be divested are Alkeran (excluding US), Kemadrin, Lanvis, Leukeran, Myleran, Purinethol, Septrin and Trandate. Combined sales of these products were 56 million pounds Sterling in 2008.

The Bad Oldesloe manufacturing site produces some of the products to be divested and a number of other products previously acquired by Aspen from GSK in June 2008.

14 July 2008

Immunomedics and Nycomed have entered into a license and collaboration agreement providing Nycomed a worldwide license to develop, manufacture and commercialize veltuzumab, Immunomedics' humanized anti-CD20 antibody in the subcutaneous formulation for the treatment of all non-cancer indications.

Immunomedics will receive a non refundable initial cash payment of $40 million and could receive potential cash milestone payments of up to $580 million upon completion of certain clinical, regulatory, and sales-based milestones, as well as escalating double-digit royalties on sales of veltuzumab.

Nycomed will be responsible for all costs associated with current and future clinical development, manufacturing and commercialization of veltuzumab in subcutaneous formulation for all non-cancer indications.

Immunomedics will continue to conduct the ongoing Phase I/II trial in ITP and will be reimbursed by Nycomed for all such expenses.

19 Jan 2010

Immunomedics have received $5 million from Nycomed for reaching the first clinical milestone event.

25 May 2010

Immunomedics has received $5 million from Nycomed for reaching a clinical milestone.

17 April 2008

Worldwide strategic alliance to discover, develop and market novel microRNA-targeted therapeutics to treat inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.

The alliance leverages Regulus’ unique expertise and intellectual property position in the discovery and development of microRNA-targeted therapeutics and provides GSK with an option to license product candidates directed at four different microRNA targets with relevance in inflammatory disease.

Regulus will be responsible for the discovery and development of the microRNA antagonists through completion of clinical proof of concept, unless GSK chooses to exercise its option earlier.

After exercise of the option, GSK will have an exclusive license to drugs developed under each program by Regulus for the relevant microRNA target for further development and commercialization on a worldwide basis.

Regulus will have the right to further develop and commercialize any microRNA therapeutics which GSK chooses not to develop or commercialize.

Regulus will receive $20 million in upfront payments from GSK, including a $15 million option fee and a $5 million note (guaranteed by Isis and Alnylam) that will convert into Regulus common stock in the future under certain specified circumstances.

Regulus could also be eligible to receive up to $144.5 million in development, regulatory and sales milestone payments for each of the four microRNA-targeted therapeutics discovered and developed as part of the alliance.

In addition to the potential of nearly $600 million Regulus could receive in option, license and milestone payments, Regulus would also receive tiered royalties up to double digits on worldwide sales of products resulting from the alliance.

10-year, $550 million agreement with Bristol-Myers Squibb for a range of finance and accounting and application development and maintenance services.

The “bundled” services agreement extends a four-year outsourcing agreement the two companies signed in 2004 for application maintenance and accounts payable services and expands the scope to include additional application maintenance services, application development services and global financial support services.

Accenture will provide these services to Bristol-Myers Squibb in the Americas, Asia, and EMEA regions in 22 languages through Accenture’s Global Delivery Network, which includes more than 50 delivery centers across five continents.

The agreement provides dedicated global IT and financial support services to Bristol-Myers Squibb to help achieve operational cost savings and flexibility.

The agreement is also designed to enable Bristol-Myers Squibb to more effectively manage its business, by providing a variable cost structure to address varying economic factors, such as patent lifecycles.

Strategic alliance for the development, commercialization and supply of XIAFLEX(TM) (clostridial collagenase for injection), a novel, first-in-class, late-stage biologic, for the treatment of Dupuytren's contracture and Peyronie's disease.

Pfizer will receive exclusive rights to commercialize XIAFLEX in the 27 member countries of the European Union (EU) and 19 other European and Eurasian countries.

In addition, Pfizer will be primarily responsible for regulatory activities for XIAFLEX in these countries.

Pfizer will make an up-front payment of $75 million to Auxilium and up to $410 million in potential milestone payments, with $150 million tied to regulatory milestones and $260 million based on sales milestones.

Auxilium will receive increasing tiered royalties based on sales of XIAFLEX in Pfizer's territories.

Auxilium will remain primarily responsible for the global development of XIAFLEX and will be responsible for all clinical and commercial drug manufacturing and supply.

Pfizer will share clinical development costs for certain trials required for the EU and be responsible for all discretionary development within the countries for which it has exclusive rights to commercialize XIAFLEX.

Pfizer will have a right of negotiation to obtain exclusive rights to commercialize XIAFLEX pipeline indications in its territories.

Amgen will receive an exclusive license to develop and commercialize Kyowa Hakko's humanized monoclonal antibody KW-0761 worldwide, except in Japan, Korea, China and Taiwan.

Kyowa Hakko will retain the development and commercialization rights in these countries.

Amgen will make an upfront payment to Kyowa Hakko of $100 million.

Kyowa Hakko could receive up to $420 million in additional payments, including development, approval and sales milestones.

Kyowa Hakko will also be entitled to receive double digit royalties on sales.

KW-0761 is currently being studied in inflammation and oncology settings. Kyowa Hakko has completed Phase 1 studies of KW-0761 in healthy volunteers and allergic rhinitis patients, and is currently conducting Phase 1 studies of KW-0761 in lymphoma patients.

Amgen will initially acquire rights in all non-oncology indications, and Kyowa Hakko will continue its development activities in oncology until the completion of Phase 2a.

At that time, Amgen may elect to reimburse Kyowa Hakko for its oncology-related development costs, expand its license to include oncology and assume the development and commercialization of KW-0761 in oncology settings.

21 October 2011

ImmuPharma announced that following discussions with Cephalon, its licensee for Lupuzor, it has regained rights to Lupuzor, due to the acquisition of Cephalon by Teva Pharmaceutical.

25 November 2008

Cephalon will pay ImmuPharma a $15 million upfront option payment.

If the Phase IIb studies are successful and if the option is exercised then the parties enter into an exclusive worldwide license agreement and ImmuPharma will receive a one-time license fee, milestone payments upon the achievement of regulatory milestones and royalties on commercial sales of Lupuzor.

The various milestone payments which include sales milestones may total up to $500 million.

Upon exercise of the option, Cephalon will assume all expenses for Phase III studies and subsequent commercialization of the product.

2 February 2009

Cephalon will exercise its option to license worldwide rights to Lupuzor

Research alliance focused on the research, development and commercialisation of novel drugs for the treatment of cancer.

The new agreement grants Janssen Pharmaceutica a worldwide exclusive license to compounds arising from Astex’s novel FGFR inhibitor programme, and the parties are also to establish a new drug discovery alliance focused on the identification of novel inhibitors against a further two cancer drug targets.

Ortho Biotech Research & Development, the research and development arm of Janssen Pharmaceutica, will be responsible for completing all of the pre-clinical and clinical development of all products arising from the collaboration and for their commercialisation globally.

The agreement also grants Astex an option to co-commercialise FGFR products developed under the collaboration in the USA.

The agreement provides for an upfront payment and equity investment in Astex, plus committed research funding, totalling $37.4 million over a two year period, as well as downstream development and regulatory milestones relating to all three programmes.

Astex will also receive tiered, double digit, royalties on sales of FGFR inhibitor products discovered and developed under the collaboration and additional royalties on new products generated under the other research programmes.

Total payments under the collaboration, excluding royalties, could be worth over $500 million to Astex, assuming one product from each programme is successfully commercialised in all territories.

12 February 2008

Sanofi-Aventis has an exclusive worldwide license for the development and commercialization of Dyax's fully human monoclonal antibody DX-2240, as well as a worldwide non exclusive license to Dyax’s proprietary antibody phage display technology.

Dyax could receive up to $500 million in license fees and milestone payments, in the case of full commercial success of the first 5 antibody candidates, including DX-2240 for which $25 million are due in 2008.

Dyax will receive royalties on net sales on antibody candidates.

Sanofi-Aventis will be responsible for the development, registration, and commercialization and will book the sales worldwide.

For certain antibody product candidates discovered by sanofi-aventis, Dyax will retain co-development and profit sharing rights, while sanofi-aventis will maintain the leadership in development, marketing and the consolidation of sales.